0001493152-19-012548.txt : 20190814 0001493152-19-012548.hdr.sgml : 20190814 20190814162136 ACCESSION NUMBER: 0001493152-19-012548 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Akers Biosciences, Inc. CENTRAL INDEX KEY: 0001321834 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36268 FILM NUMBER: 191026723 BUSINESS ADDRESS: STREET 1: 201 GROVE RD CITY: THOROFARE STATE: NJ ZIP: 08086 BUSINESS PHONE: 856-848-8698 MAIL ADDRESS: STREET 1: 201 GROVE RD CITY: THOROFARE STATE: NJ ZIP: 08086 FORMER COMPANY: FORMER CONFORMED NAME: Akers Biosciences Inc DATE OF NAME CHANGE: 20050325 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2019

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File No. 001-36268

AKERS BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

New Jersey

22-2983783

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification No.)

201 Grove Road

Thorofare, NJ 08086

(Address of principal executive offices)

(856) 848-8698

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]
Non-accelerated filer	[X]	Smaller reporting company	[X]
		Emerging growth company	[X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, no par value		AKER		NASDAQ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

As of August 9, 2019, there were 12,512,708 shares outstanding of the registrant’s Common Stock.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	3

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	31

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	40

Item 4.	Controls and Procedures	40

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	41

Item 1A.	Risk Factors	44

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44

Item 3.	Defaults Upon Senior Securities	44

Item 4.	Mine Safety Disclosures	44

Item 5.	Other Information	44

Item 6.	Exhibits	44

Signatures		45

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

June 30, 2019 and December 31, 2018

	As of
	June 30, 2019			December 31, 2018
	(unaudited)			(audited)
ASSETS
Current Assets
Cash	$	248,439		$	181,755
Marketable Securities		4,020,498			5,272,998
Trade Receivables, net		266,860			176,326
Deposits and other receivables		-			9,347
Inventories, net		544,241			585,267
Prepaid expenses		169,591			444,435

Total Current Assets		5,249,629			6,670,128

Non-Current Assets
Prepaid expenses		267,569			298,256
Restricted Cash		115,094			500,000
Property, Plant and Equipment, net		68,481			83,456
Intangible Assets, net		223,407			243,411
Other Assets		7,672			12,002

Total Non-Current Assets		682,223			1,137,125

Total Assets	$	5,931,852		$	7,807,253

LIABILITIES
Current Liabilities
Trade and Other Payables		1,617,718			1,973,500

Total Liabilities		1,617,718			1,973,500

Commitments and Contingencies

SHAREHOLDERS’ EQUITY
Convertible Preferred Stock, No par value, 50,000,000 shares authorized, 0 and 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018		-			-
Common Stock, No par value, 500,000,000 shares authorized, 12,508,958 and 12,482,708 issued and outstanding as of June 30, 2019 and December 31, 2018		121,699,375			121,554,547
Accumulated Other Comprehensive Income (Loss)		21,489			(25,913	)
Accumulated Deficit		(117,406,730	)		(115,694,881	)

Total Shareholders’ Equity		4,314,134			5,833,753

Total Liabilities and Shareholders’ Equity	$	5,931,852		$	7,807,253

The accompanying notes are an integral part to these condensed consolidated financial statements.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations and Comprehensive Loss

For the Three and Six Months Ended June 30, 2019 and 2018

(unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2019			2018			2019			2018

Product Revenue	$	464,513		$	526,601		$	1,076,634		$	829,076
Product Cost of Sales		(219,864	)		(302,826	)		(465,801	)		(600,326	)
Gross Income		244,649			223,775			610,833			228,750

Administrative Expenses		981,309			1,565,602			1,964,265			2,481,134
Sales and Marketing Expenses		14,139			469,469			163,979			969,620
Compliance, Research and Development Expenses		60,909			259,124			149,300			699,094
Litigation Settlement Expenses		-			-			75,000			-
Amortization of Non-Current Assets		10,002			42,777			20,004			85,554

Loss from Operations		(821,710	)		(2,113,197	)		(1,761,715	)		(4,006,652	)

Other (Income)/Expenses
Foreign Currency Transaction Loss		219			3,029			4,878			5,905
Loss on Investments		543			4,400			4,258			4,401
Interest and Dividend Income		(27,581	)		(53,173	)		(59,002	)		(89,514	)
Total Other Income		(26,819	)		(45,744	)		(49,866	)		(79,208	)

Loss Before Income Taxes		(794,891	)		(2,067,453	)		(1,711,849	)		(3,927,444	)

Income Tax Benefit		-			-			-			-

Net Loss		(794,891	)		(2,067,453	)		(1,711,849	)		(3,927,444	)

Other Comprehensive Gain/(Loss)
Net Unrealized Gain/(Loss) on Marketable Securities		18,059			4,401			47,402			(12,443	)
Total Other Comprehensive Gain/(Loss)		18,059			4,401			47,402			(12,443	)

Comprehensive Loss	$	(776,832	)	$	(2,063,052	)	$	(1,664,447	)	$	(3,939,887	)

Basic and Diluted loss per common share	$	(0.06	)	$	(0.18	)	$	(0.14	)	$	(0.38	)

Weighted average basic and diluted common shares outstanding		12,500,923			11,656,788			12,492,115			10,293,569

The accompanying notes are an integral part to these condensed consolidated financial statements.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(unaudited)

	For the Six Months Ended June 30, 2019
	Preferred				Common									Accumulated
	Shares				Shares									Other
	Issued and		Preferred		Issued and		Common		Deferred		Accumulated			Comprehensive			Total
	Outstanding		Stock		Outstanding		Stock		Compensation		Deficit			Income/(Loss)			Equity

Balance at December 31, 2018 (audited)		-	$	-		12,482,708	$	121,554,547	$	-	$	(115,694,881	)	$	(25,913	)	$	5,833,753

Net loss		-		-		-		-		-		(916,958	)		-			(916,958	)
Issuance of unrestricted stock to a key employee		-		-		15,000		15,874		-		-			-			15,874
Issuance of restricted stock units to directors for services		-		-		-		3,906		-		-			-			3,906
Net unrealized gain on marketable securities		-		-		-		-		-		-			29,343			29,343

Balance at March 31, 2019 (unaudited)		-		-		12,497,708		121,574,327		-		(116,611,839	)		3,430			4,965,918
Net loss		-		-		-		-		-		(794,891	)		-			(794,891	)
Issuance of unrestricted stock to a key employee		-		-		11,250		6,570		-		-			-			6,570
Issuance of restricted stock units to directors for services		-		-		-		118,478		-		-			-			118,478
Net unrealized gain on marketable securities		-		-		-		-		-		-			18,059			18,059

Balance at June 30, 2019 (unaudited)		-		-		12,508,958		121,699,375		-		(117,406,730	)		21,489			4,314,134

	For the Six Months Ended June 30, 2018
	Preferred						Common										Accumulated
	Shares						Shares										Other
	Issued and			Preferred			Issued and		Common		Deferred			Accumulated			Comprehensive			Total
	Outstanding			Stock			Outstanding		Stock		Compensation			Deficit			Income/(Loss)			Equity

Balance at December 31, 2017 (audited)		1,755		$	1,755,000			5,534,692	$	110,647,169	$	(3,469	)	$	(104,845,847	)	$	-		$	7,552,853

Net loss		-			-			-		-		-			(1,859,991	)		-			(1,859,991	)
Exercise of warrants for common stock		-			-			3,811,509		5,717,325		-			-			-			5,717,325
Conversion of preferred stock to common stock		(1,755	)		(1,755,000	)		1,464,930		1,755,000		-			-			-			-
Amortization of deferred compensation		-			-			-		-		3,469			-			-			3,469
Issuance of unrestricted stock to a key employee		-			-			3,125		5,175		-			-			-			5,175
Issuance of non-qualified stock options to key employees		-			-			-		2,712		-			-			-			2,712
Issuance of restricted stock for services to non-employees		-			-			-		12,545		-			-			-			12,545
Net unrealized loss on marketable securities		-			-			-		-		-			-			(16,843	)		(16,843	)

Balance at March 31, 2018 (unaudited)		-			-			10,814,256		118,139,926		-			(106,705,838	)		(16,843	)		11,417,245
Net loss		-			-			-		-		-			(2,067,453	)		-			(2,067,453	)
Exercise of warrants for common stock		-			-			966,506		1,437,875		-			-			-			1,437,875
Conversion of preferred stock to common stock		-			-			-		-		-			-			-			-
Amortization of deferred compensation		-			-			-		-		-			-			-			-
Issuance of unrestricted stock to a key employee		-			-			-		-		-			-			-			-
Issuance of non-qualified stock options to key employees		-			-			-		2,742		-			-			-			2,742
Issuance of restricted stock for services to non-employees		-			-			-		-		-			-			-			-
Net unrealized loss on marketable securities		-			-			-		-		-			-			4,400			4,400

Balance at June 30, 2018 (unaudited)		-			-			11,780,762		119,580,543		-			(108,773,291	)		(12,443	)		10,794,809

The accompanying notes are an integral part of these condensed consolidated financial statements.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2019 and 2018

(unaudited)

	For the Six Months Ended June 30,
	2019			2018

Cash flows from operating activities
Net loss	$	(1,711,849	)	$	(3,927,444	)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued income on marketable securities		3,514			(16,332	)
Depreciation and amortization		34,979			112,903
Reserve for obsolete inventory		-			32,283
Reserve for doubtful accounts		4,247			97,000
Loss on sales of securities		4,258			-
Amortization of deferred compensation		-			3,469
Share based compensation to employees - options		-			5,454
Share based compensation to an employee		22,444			-
Share based compensation to directors - restricted stock units		122,384			5,175
Share based compensation to non-employees - restricted stock		-			12,545
Changes in assets and liabilities:
(Increase)/decrease in trade receivables		(94,781	)		455,048
(Increase)/decrease in deposits and other receivables		9,347			(43,941	)
(Increase)/decrease in inventories		41,026			(99,220	)
(Increase)/decrease in prepaid expenses		305,531			(521,676	)
Decrease in other assets		4,330			-
Increase/(decrease) in trade and other payables		(355,782	)		66,844
Net cash used in operating activities		(1,610,352	)		(3,817,892	)

Cash flows from investing activities
Purchases of property, plant and equipment		-			(37,698	)
Purchases of marketable securities		(62,516	)		(5,268,754	)
Proceeds from sale of marketable securities		1,354,646			2,306,675
Net cash provided by/(used in) investing activities		1,292,130			(2,999,777	)

Cash flows from financing activities
Net proceeds from exercise of warrants for common stock		-			7,155,200
Net cash provided by financing activities		-			7,155,200

Net increase/(decrease) in cash and restricted cash		(318,222	)		337,531
Cash and restricted cash at beginning of period		681,755			438,432
Cash and restricted cash at end of period	$	363,533		$	775,963

Supplemental cash flow information:
Cash paid for:
Interest	$	-		$	-
Income Taxes	$	-		$	-

Supplemental Schedule of Non-Cash Financing and Investing Activities
Net unrealized gains/(losses) on marketable securities	$	47,402		$	(12,443	)
Conversion of Series B Preferred Stock to common shares	$	-		$	1,755,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 1 – Organization and Description of Business

Akers Biosciences, Inc. (“Akers”), is a New Jersey corporation. These condensed consolidated financial statements include two wholly owned subsidiaries, Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation, (together, the “Company”). All material intercompany transactions have been eliminated in consolidation.

On November 7, 2018, the Company announced its intention to explore strategic alternatives in order to maximize shareholder value. As announced, this process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities.

Furthermore, the Company has undertaken steps to reduce its expenses, including reducing the number of personnel, reducing its office footprint, eliminating services from non-critical vendors and has withdrawn its shares from registration on the AIM exchange in the United Kingdom.

The Company’s medical device business has as its current focus the production and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s principal products are a rapid test detecting the antibody causing an allergic reaction to Heparin, breath alcohol detectors used for health and safety and a consumer product used to screen for levels of cholesterols.

Note 2 – Significant Accounting Policies

(a)

Basis of Presentation

The Condensed Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP).

Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed. As such, the information included in these financial statements should be read in conjunction with the audited financial statements as of and for the years ended December 31, 2018 and 2017 included in the Company’s 2018 Form 10-K, as filed on April 1, 2019. In the opinion of the management, these condensed consolidated financial statements include all adjustments, consisting of only normal recurring nature, necessary for a fair statement of the financial position of the Company as of June 30, 2019 and its results of operations and cash flows for the three and six months ended June 30, 2019 and 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2019.

The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements.

(b)

Use of Estimates and Judgments

The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for revenue recognition, allowances for doubtful accounts, inventory write-downs, impairment of intangible assets and valuation of share-based payments.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(c)

Functional and Presentation Currency

These condensed consolidated financial statements are presented in U.S. Dollars, which is the Company’s functional currency. All financial information presented in U.S. Dollars has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated in Foreign Currencies, are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

(d)

Comprehensive Income (Loss)

The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income (loss). Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income.

(e)

Cash and Cash Equivalents

The Company considers all highly liquid investments, which include short-term bank deposits (up to 3 months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents.

(f)

Restricted Cash

At June 30, 2019, restricted cash included in non-current assets on the Company’s consolidated balance sheet was $115,094 representing cash in trust for the purpose of funding legal fees for certain litigations.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(g)

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities.

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

	Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

	Level 2	Inputs to the valuation methodology include:

	●	quoted prices for similar assets or liabilities in active markets;

	●	quoted prices for identical or similar assets or liabilities in inactive markets;

	●	inputs other than quoted prices that are observable for the asset or liability;

	●	inputs that are derived principally from or corroborated by observable market data by correlation or other means

	If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3

Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

Following is a description of the valuation methodologies used for assets measured at fair value as of June 30, 2019 and December 31, 2018.

U.S. Agency Securities: Valued using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at June 30, 2019	$	-	$	4,020,498	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

Marketable securities include U.S. agency securities, which are classified as available for sale. The securities are valued at fair market value. Maturities of the securities are less than one year. Unrealized gains and losses relating to the available for sale investment securities were recorded in the Condensed Consolidated Statement of Changes in Shareholders’ Equity as comprehensive (loss) income. These amounts were $18,059 and $47,402 in unrealized gain for the three and six months ended June 30, 2019 and a decrease of $4,401 and an increase of $12,443 in unrealized loss for the three and six months ended June 30, 2018, respectively.

Gains and losses resulting from the sales of marketable securities were a loss of $543 and $4,400 for the three months ended June 30, 2019 and 2018, and a loss of $4,258 and $4,401 for the six months ended June 30, 2019 and 2018, respectively.

Proceeds from the sale of marketable securities in the three and six months ended June 30, 2019 were $502,126 and $1,354,646, respectively and in the three and six months ended June 30, 2018 were $2,004,580 and $2,306,675, respectively.

(h)

Trade Receivables and Allowance for Doubtful Accounts

The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature.

The normal credit terms extended to customers ranges between 30 and 90 days. Credit terms longer than these may be extended after considering the credit worthiness of the customers and the business requirements. The Company reviews all receivables that exceed terms and establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade and other receivables. A considerable amount of judgment is required in assessing the amount of allowance. The Company considers the historical level of credit losses, makes judgments about the credit worthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future.

As of June 30, 2019 and December 31, 2018, allowances for doubtful accounts for trade receivables were $605,848 and $606,835. Bad debt expenses for trade receivables were $0 and $125,500 for the three months ended June 30, 2019 and 2018, respectively and $4,247 and $125,500 for the six months ended June 30, 2019 and 2018, respectively.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(i)

Concentrations

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks is in excess of the FDIC insurance limit. The Company has not experienced any loss as a result of these cash deposits. These cash balances are maintained with two banks.

Major Customers

For the three months ended June 30, 2019, three customers generated 42%, 20%, and 19% or 81% in the aggregate, of the Company’s revenue. For the six months ended June 30, 2019, two customers generated 44% and 34%, or 78% in the aggregate, of the Company’s revenue.

For the three months ended June 30, 2018, three customers generated 33%, 27%, and 12%, or 72% in aggregate, of the Company’s revenue. For the six months ended June 30, 2018, two customers generated 49% and 17%, or 66% in the aggregate, of the Company’s revenue.

Two customers accounted for 53% and 23%, or 76% in the aggregate, of gross trade receivables, before accounting for allowance for doubtful accounts, as of June 30, 2019. As of June 30, 2019, the Company had $458,902 and $201,330 in trade receivables, respectively, from these customers. These concentrations make the Company vulnerable to a near-term severe impact should these relationships be terminated. The largest of these customer balances was fully reserved as of June 30, 2019, and on June 21, 2019, this customer filed suit against the Company (see note 7).

Two customers accounted for 59% and 14%, or 73% in the aggregate, of gross trade receivables, before accounting for allowance for doubtful accounts, as of December 31, 2018. As of December 31, 2018, the Company had $458,902 and $111,037 in trade receivables, respectively, from these customers. These concentrations make the Company vulnerable to a near-term severe impact should these relationships be terminated. The largest of these customer balances was fully reserved as of December 31, 2018, and on June 21, 2019, this customer filed suit against the Company (see note 7).

To limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition.

Major Suppliers

For the three months ended June 30, 2019, two suppliers accounted for 66% and 10%, or 76%, in the aggregate, of the Company’s purchases. For the six months ended June 30, 2019, one supplier accounted for 50%, of the Company’s purchases.

For the three months ended June 30, 2018, two suppliers accounted for 13% and 11%, or 24% in the aggregate, of the Company’s purchases. For the six months ended June 30, 2018, no supplier accounted for 10% or more of the Company’s purchases.

Three vendors accounted for 70% in the aggregate, of trade payables as of June 30, 2019. As of June 30, 2019, the Company had $180,114, $123,000, and $116,206 in trade payables, respectively, to these vendors.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(j)

Property, Plant and Equipment

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “other income” in the Condensed Consolidated Statement of Operations and Comprehensive Loss.

Depreciation is recognized in profit and loss on the accelerated basis over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives.

Depreciation expense totaled $9,542 and $13,675 for the three months ended June 30, 2019 and 2018, respectively and $14,975 and $27,350 for the six months ended June 30, 2019 and 2018, respectively.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(k)

Intangible Assets

The Company’s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount, other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge to our condensed consolidated statements of operations and comprehensive loss.

Intangible assets as of June 30, 2019 and December 31, 2018 were $223,407 and $243,411, respectively. Intangible assets at June 30, 2019 consisted of patents, trademarks and customer lists of $3,897,635 net of accumulated amortization and impairment of $3,674,228.

Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. Amortization expense was $10,002 and $42,777 for the three months ended June 30, 2019 and 2018, respectively and $20,004 and $85,553 for the six months ended June 30, 2019 and 2018, respectively.

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2019 (six months)	$	20,004
2020		40,008
2021		40,008
2022		40,008
2023		40,008
Thereafter		43,371
	$	223,407

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(l)

Revenue Recognition

Beginning on January 1, 2019, the Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle:

Step 1: Identify the contract with the customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when the company satisfies a performance obligation

The Company does not have any significant contracts with customers requiring performance beyond delivery. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control of the product transfers to our customer, which generally occurs upon delivery to the customer but can also occur when goods are shipped by the Company, depending on the shipment terms of the contract. The Company’s performance obligations are satisfied at that time.

The Company uses the most likely amount approach to determine the variable consideration of the transaction price in order to account for the contractual rebates and incentives that are estimated and adjusted for over time. The Company provides for rebates to its distributors. The Company had accrued for rebates and incentives of $1,000 and $23,179, as of June 30, 2019 and December 31, 2018. Accounts receivable will be reduced when the rebates are applied by the customer. The Company recognized $7,679 and $6,350 during the three months ended June 30, 2019 and 2018 and $16,377 and $43,894 for the six months ended June 30, 2019 and 2018 for rebates, which is included as a reduction of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss.

(m)

Income Taxes

The Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.

The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management’s opinion, adequate provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(n)

Income Taxes, continued

Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of June 30, 2019 and December 31, 2018, no liability for unrecognized tax benefits was required to be reported.

There is no income tax benefit for the losses for the three and six months ended June 30, 2019 and 2018 since management has determined that the realization of the net deferred assets is not assured and has created a valuation allowance for the entire amount of such tax benefits.

The Company’s policy for recording interest and penalties associated with tax audits is to record such items as a component of general and administrative expense. There were no amounts accrued for penalties and interest for the three and six months ended June 30, 2019 and 2018. The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(o)

Shipping and Handling Fees and Costs

The Company charges actual shipping costs plus a handling fee to customers, which amounted to $9,511 and $18,739 for the three months ended June 30, 2019 and 2018 and $21,997 and $32,380 for the six months ended June 30, 2019 and 2018, respectively. These fees are classified as part of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as product cost of sales, which amounted to $15,660 and $37,993 for the three months ended June 30, 2019 and 2018, respectively and $27,579 and $64,937 for the six months ended June 30, 2019 and 2018, respectively.

(p)

Basic and Diluted Earnings per Share of Common Stock

Basic earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.

The calculation of basic and diluted loss per share for the three months ended June 30, 2019 and 2018 was based on the net loss of $794,891 and $2,067,453, respectively and $1,711,849 and $3,927,444 for the six months ended June 30, 2019 and 2018, respectively. The basic and diluted weighted average number of common shares outstanding for the three months ended June 30, 2019 and 2018 was 12,500,923 and 11,656,788, respectively and 12,492,115 and 10,293,569 for the six months ended June 30, 2019 and 2018, respectively.

Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Three and Six Months Ended June 30,
	2019		2018
Stock Options		4,064		25,250
RSUs		374,481		-
Warrants		2,110,737		1,416,229
Total potentially dilutive shares		2,489,282		1,441,479

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(q)

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements Adopted

As the Company is an emerging growth company (“EGC”), it has elected to adopt recently issued accounting pronouncements based on effective dates applicable to other than public business entities. The Company is expected to lose its EGC status on December 31, 2019 as it is the last day of the fiscal year following the fifth anniversary of the effective date of its registration statement on January 23, 2014.

In May 2014 and April 2016, the FASB issued ASU No. 2014-09 and ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, FASB issued ASU 2015-14 which deferred the effective date of Update 2014-09 to annual reporting periods beginning after December 15, 2018 for entities other than public business entities, and to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period for public business entities.

The Company has elected to apply the modified retrospective method and the impact was determined to be immaterial on the condensed consolidated financial statements. Accordingly, the new revenue standard was applied prospectively in our condensed consolidated financial statements from January 1, 2019 forward and reported financial information for historical comparable periods will not be revised and will continue to be reported under the accounting standards in effect during those historical periods.

The Company has performed an analysis and identified its revenues and costs that are within the scope of the new guidance. The Company has determined that its methods of recognizing revenues will not be significantly impacted by the new guidance.

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for public business entities, certain not-for-profit entities, and certain employee benefit plans for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, ASU 2018-07 is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASC 2018-07 effective January 1, 2019. There was no material impact on the Company’s condensed consolidated financial statements upon this adoption.

In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements, to makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the Accounting Standards Codification. Certain items of the amendments in ASU 2018-09 will be effective for the Company in annual periods beginning after December 15, 2018. The adoption of ASU 2018-09 did not have a material impact on the Company’s condensed consolidated financial statements.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 2 - Significant Accounting Policies, continued

(q)

Recently Issued Accounting Pronouncements, continued

Recently Issued Accounting Pronouncements Not Adopted

In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842) (“ASU-2016-02”), which requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor, and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the effect this guidance will have on its condensed consolidated financial statements and related disclosure, and anticipates the guidance to result in increases in its assets and liabilities as most of its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and lease liabilities.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments (“ASU-2016-13”). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2019, including interim periods within that fiscal year. The Company is currently evaluating the effect this guidance will have on its condensed consolidated financial statements and related disclosures.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 3 – Recent Developments and Management’s Plans

On December 19, 2018, the Company announced its intent to delist from the AIM Market of the London Stock Exchange. The Company believed that due to the relatively low liquidity in the Company’s common stock, remaining listed on the AIM Market did not merit the ongoing costs and regulatory complexities associated with maintaining the AIM listing. On March 5, 2019, the Company held a special meeting of shareholders who then voted in favor of the Company delisting from the AIM Market. The delisting took effect on March 29, 2019.

On November 7, 2018, the Company announced that its board of directors had initiated a process to evaluate strategic alternatives to maximize shareholder value. This process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities. On November 19, 2018, the Company further announced that in its evaluation of strategic alternatives it will consider a range of potential strategic alternatives including, but not limited to, business combinations in sectors different than that currently engaged in, including cannabis and hemp related industries.

By way of a letter dated May 10, 2019, the Listing Qualifications Department of NASDAQ advised the Company that it did not comply with NASDAQ Listing Rule 5550(a)(2) for continued listing, because the Company’s common stock did not meet NASDAQ’s minimum $1.00 bid price requirement (the “Price Requirement”). The Company intends to monitor the closing bid price of the common stock and may, if appropriate, consider implementing available options to regain compliance with the Price Requirement under the NASDAQ Listing Rules.

Historically, the Company has relied upon public offerings and private placements of common stock to raise operating capital. As of August 9, 2019, the Company had cash and marketable securities of approximately $3.99 million (excluding restricted cash of $115,094) and working capital of approximately $3.53 million.

The Company anticipates that available cash and marketable securities, as well as expected cash from operations, will be sufficient to meet its obligations as they fall due within one year after these financial statements are issued.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 4 – Inventories

Inventories are measured at the lower of cost or net realizable value. The cost of inventories is based on the weighted-average principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, costs include an appropriate share of production overhead based on normal operating capacity.

Inventories consist of the following:

	June 30, 2019			December 31, 2018

Raw Materials	$	404,094		$	542,761
Sub-Assemblies		686,386			711,181
Finished Goods		479,457			635,565
Reserve for Obsolescence		(1,025,696	)		(1,304,240	)
	$	544,241		$	585,267

Obsolete inventory charged to cost of goods was $41,849 and $7,477, during the three months ended June 30, 2019 and 2018, and $45,946 and $28,987 during the six months ended June 30, 2019 and 2018, respectively.

Note 5 - Trade and Other Payables

Trade and other payables consists of the following:

	June 30, 2019		December 31, 2018

Trade Payables	$	741,875	$	686,578
Accrued Expenses		816,093		1,227,172
Deferred Compensation		59,750		59,750
	$	1,617,718	$	1,973,500

See also Note 9 for related party information.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 6 - Share-based Payments

Equity incentive Plans

2013 Stock Incentive Plan

On January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (“2013 Plan”). The 2013 Plan was amended by the Board on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides for the issuance of up to 103,750 shares of the Company’s common stock. As of June 30, 2019, grants of restricted stock and options to purchase 71,590 shares of Common Stock have been issued pursuant to the 2013 Plan, and 32,160 shares of Common Stock remain available for issuance.

2017 Stock Incentive Plan

On August 7, 2017, the shareholders approved and the Company adopted the 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan provides for the issuance of up to 168,750 shares of the Company’s common stock. As of June 30, 2019, grants of restricted stock and options to purchase 62,282 shares of Common Stock have been issued pursuant to the 2017 Plan, and 106,468 shares of Common Stock remain available for issuance.

2018 Stock Incentive Plan

On December 7, 2018, the shareholders approved and the Company adopted the 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the issuance of up to 1,875,000 shares of the Company’s common stock. As of June 30, 2019, grants of RSUs to purchase 374,481 shares of Common Stock have been issued pursuant to the 2018 Plan, and 1,500,519 shares of Common Stock remain available for issuance.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 6 - Share-based Payments, continued

Stock Options

The following table summarizes the option activities for the six months ended June 30, 2019:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		10,502		$	30.41	$	17.42		1.43	$	-
Granted		-			-		-		-		-
Exercised		-			-		-		-		-
Forfeited		(6,438	)		33.79		23.72		0.58		-
Canceled/Expired		-			-		-		-		-
Balance at June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-
Exercisable as of June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.45 for the Company’s common shares on June 30, 2019. As the closing stock price on June 30, 2019 is lower than the exercise price, there is no intrinsic value to disclose.

As of June 30, 2019, all of the Company’s outstanding stock options were fully vested and exercisable.

During the three months ended June 30, 2019 and 2018, the Company incurred stock option expenses totaling $0 and $2,742, respectively and $0 and $5,454 for the six months ended June 30, 2019 and 2018, respectively.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 6 - Share-based Payments, continued

Restricted Stock Units

On March 29, 2019, the Compensation Committee of the Board of Directors approved the grant of 124,827 Restricted Stock Units (“RSU”) to each of the three directors. Each RSU had a grant date fair value of $0.97 which shall be amortized on a straight-line basis over the vesting period into administrative expenses within the Condensed Consolidated Statement of Operations and Comprehensive Loss. Such RSUs were granted under the 2018 Plan, and shall vest on January 1, 2020, with vesting accelerated upon a change of control. Upon vesting, such RSUs are settled with the issuance of common stock, including on a net of tax basis, at the discretion of the holder.

At June 30, 2019, the unamortized value of the RSU’s was $240,863. The unamortized amount will be expensed over the remaining period of six months. A summary of activity related to RSUs for the six months ended June 30, 2019 is presented below:

	Number of RSUs		Weighted Average Grant Date Fair Value
Balance at December 31, 2018		-	$	-
Granted		374,481	$	0.97
Exercised		-		-
Forfeited		-		-
Canceled/Expired		-		-
Balance at June 30, 2019		374,481	$	0.97
Exercisable as of June 30, 2019		-		-

During the three and six months ended June 30, 2019, the Company incurred RSU expense of $118,478 and $122,384, respectively.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 6 - Share-based Payments, continued

Stock Warrants

The table below summarizes the warrant activity for the period ended June 30, 2019:

	Number of Warrants		Weighted Average Exercise Price		Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		2,110,737	$	3.10		4.21	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Canceled/Expired		-		-		-		-
Balance at June 30, 2019		2,110,737	$	3.10		3.71	$	-
Exercisable as of June 30, 2019		2,110,737	$	3.10		3.71	$	-

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 7 – Equity

During the six months ended June 30, 2019, the Company issued 26,250 shares of Common Stock to Mr. Yeaton pursuant to his employment agreement. These shares had a fair value of $22,444 on the date of grant, of which $4,238 was recorded in trade and other payables in the consolidated balance sheet as of December 31, 2018 and $6,570 and $18,206 were recorded as expense in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2019 and 2018, respectively.

Note 8 – Commitments and Contingencies

Lease Commitments

The Company leases its facility in West Deptford, New Jersey under an operating lease (“Thorofare Lease”) with annual rentals of $132,000 plus common area maintenance (CAM) charges. The lease, which took effect on January 1, 2008, reduced the CAM charges allowing the Company to reach their own agreements with utilities and other maintenance providers. On January 7, 2013, the Company extended its lease agreement for a term of 7 years, expiring December 31, 2019. Rent expense for the Thorofare Lease, including related CAM charges for the three months ended June 30, 2019 and 2018 totaled $40,955 and $40,928, respectively and $82,320 and $83,144 for the six months ended June 30, 2019 and 2018, respectively. The Company entered into a 24-month lease for a satellite office located in Ramsey, New Jersey (“Ramsey Lease”) with annual rents of $25,980 plus common area maintenance (CAM) charges. The lease took effect on June 1, 2017 and ran through May 31, 2019. Rent expenses for the Ramsey Lease, including related CAM charges totaled $6,495 and $6,495 for the three months ended June 30, 2019 and 2018, respectively, and $12,990 and $12,990 for the six months ended June 30, 2019 and 2018, respectively. The Company entered into a 29-month lease for warehouse space located in Pitman, New Jersey (“Pitman Lease”) with annual rents of $40,839. The lease took effect on August 1, 2017 and runs through December 31, 2019. Rent expenses for the Pitman Lease totaled $10,210 and $9,913 for the three months ended June 30, 2019 and 2018, and $20,420 and $19,825 for the six months ended June 30, 2019 and 2018, respectively. A security deposit of $4,950 is included in other assets on the Condensed Consolidated Balance Sheet.

The Company entered into a 60-month operating lease for equipment with annual rentals of $6,156 on September 29, 2014. The lease commenced on October 21, 2014 upon the delivery of the equipment.

The schedule of lease commitments is as follows:

	Thorofare		Pitman		Equipment
	Lease		Lease		Lease		Total
Next 6 Months	$	66,000	$	19,824	$	3,078	$	88,902

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 8 – Commitments and Contingencies, continued

ChubeWorkx

On August 17, 2016, pursuant to a Settlement Agreement (the “Settlement Agreement”) with ChubeWorkx Guernsey Limited (“ChubeWorkx”), which settled all pending claims between the Company and ChubeWorkx. Specifically, the Company and ChubeWorkx agreed to voluntarily dismiss (i) the action in the United States Federal Court, District of New Jersey brought by the Company against ChubeWorkx for outstanding amounts due to the Company under a promissory note and (ii) the action in The High Court of Justice, Queen’s Bench Division Commercial Court, Royal Courts of Justice, United Kingdom brought by ChubeWorkx against the Company arising from an exclusive licensing agreement between ChubeWorkx and the Company (“Licensing Agreement”).

In return for the Company regaining the full rights to sell breath technology products, under the terms of the Settlement Agreement, ChubeWorkx is entitled to receive a royalty of 5% of the Company’s gross revenues (the “ChubeWorkx Royalty”) until ChubeWorkx has earned an aggregate $5,000,000, after which point ChubeWorkx will no longer be entitled to receive any royalties from the Company and the Company shall have no further obligation to ChubeWorkx. The Settlement Agreement further allows the Company to retain 50% of the ChubeWorkx Royalty until the full $549,609 cash component of the monies owed by ChubeWorkx to the Company as described above has been satisfied. The Company recorded royalty expenses of $23,520 and $27,082 for the three months ended June 30, 2019 and 2018, and $54,804 and $58,771 for the six months ended June 30, 2019 and 2018, respectively, which are included in sales and marketing expenses on the Condensed Consolidated Statement of Operations and Comprehensive Loss. As of June 30, 2019, the Company owed ChubeWorkx royalties of $11,760 which is included in trade and other payables within the condensed consolidated balance sheet.

Other terms of the Settlement included: 1) the pledge as security of all earned but unpaid royalties by the Company to ChubeWorkx all Company assets, worthy to satisfy its obligations, including all inventory and receivables, with the exception of (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; 2) the pledge as security of the settlement sum which remains unpaid by the Company to ChubeWorkx all Company (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; and 3) the grant of voting proxy by ChubeWorkx to the Company which allows the Company to vote ChubeWorkx’s shares for corporate formalities under certain conditions.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 8 – Commitments and Contingencies, continued

ChubeWorkx, continued

The pledged assets are only at risk in the event that the Company cannot satisfy any outstanding royalty payment obligations subject to various cure periods and/or through a restructuring and/or liquidation under the United States Bankruptcy laws of the Company in favor of payment of said obligation.

Litigation and Settlements

Faulkner v. Akers Biosciences, Inc., No. 2:18-cv-10521 (D.N.J.) and Gleason v. Akers Biosciences, Inc., No. 2:18-cv-10805 (D.N.J.)

On June 13, 2018, Plaintiff Tim Faulkner filed a class action complaint alleging securities violations against Akers Biosciences, Inc. (“Akers”), John J. Gormally, and Gary M. Rauch (“Individual Defendants”) (together with Akers, “Defendants”) on behalf of all persons and entities who purchased publicly traded Akers securities from May 15, 2017 through June 5, 2018 (the “Faulkner Action”). The complaint alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 against all Defendants, and violations of Section 20(a) of the Exchange Act against the Individual Defendants. In particular, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose in its first, second, and third quarter 2017 10-Qs and its 2017 10-K that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; and, (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses. On June 20, 2018, Plaintiff David Gleason filed a class action complaint under the caption Gleason v. Akers Biosciences, Inc., No. 2:18-cv-10805 (D.N.J.) based on the same allegations and causes of action (the “Gleason Action”). On November 21, 2018, the Faulkner and Gleason Actions were consolidated under the Faulkner Action docket. The parties conducted a mediation on January 10, 2019 and agreed to a settlement in principle disposing of the consolidated action as to all Defendants, including the Individual Defendants. On March 8, 2019, the parties signed a settlement agreement, subject to approval by the Court, whereby the Company agreed to pay $2,250,000 in exchange for full releases and discharge of all claims against the Company. On the same day, Lead Plaintiffs filed a motion for preliminary approval of the settlement and to establish notice procedures. On July 3, 2019, the Court granted the motion for preliminary approval and scheduled a final settlement hearing for November 8, 2019. On or about July 24, 2019, the Company’s D&O insurer sent the settlement payment of $2,250,000 to the settlement agent for the class.

Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.)

On November 9, 2018, Plaintiff Cale Watts filed a verified shareholder derivative complaint alleging violations of the Securities Exchange Act of 1934, breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on alleged material weaknesses in controls, management, and documentation (the “Watts Action”). On January 14, 2019, the parties reached an agreement in principle to settle the Watts Action that included corporate reforms and an attorneys’ fees payment of $200,000. The parties finalized a Stipulation of Settlement on March 4, 2019. On March 22, 2019, Plaintiffs filed a motion seeking (a) preliminary approval of the proposed Settlement, (b) approval of the proposed form and method of providing notice of the Settlement, and (c) scheduling a hearing for final approval of the settlement (the “Motion for Preliminary Approval”). On April 1, 2019, Tiffany Chan, Jasmine Henderson, and Don Danesh Wijesekera (the “Proposed Intervenors”) filed an Opposition to the Motion for Preliminary Approval, and a Motion to Intervene and Stay Proceedings (“Motion to Intervene and Stay”). Defendants’ Opposition to the Motion to Intervene and Stay is due August 20, 2019, and its Reply in further support of the Motion for Preliminary Approval is due August 27, 2019. The Motion for Preliminary Approval and the Motion to Intervene and Stay are currently returnable on September 3, 2019.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 8 – Commitments and Contingencies, continued

Litigation and Settlements, continued

Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.)

On February 7, 2019, Tiffany Chan, Jasmine Henderson, and Don Danesh filed a verified shareholder derivative complaint alleging violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9, breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same circumstances as the Watts Action. The Chan Action further alleges that the Company should not have settled the Watts Action because the Watts Action plaintiffs lacked standing and the settlement would cause irreparable harm to the Company and its shareholders. On April 4, 2019, the Court entered the parties’ stipulation and consent order to extend Defendants’ time to answer, move, or otherwise respond to the Complaint until 20 days after the Court (a) decides the Motion for Preliminary Approval of the Watts Settlement, (b) decides the Motion in Opposition to the Watts Settlement, (c) decides the Motion to Intervene and Stay in the Watts Action, and/or (d) stays the Watts Action.

Watts and Chan Matters – Potential Resolution

On August 12, 2019, counsel for all parties in the Watts Action and the Chan Action informed the Watts Court that they had agreed in principle to a resolution of both the Watts and Chan Actions, and expected to have finalized paperwork for the Court’s review and approval within 30-45 days. The parties have a follow-up call scheduled with the Court for October 3, 2019.

Faulkner, Gleason, Watts and Chan Matters

With respect to the Faulkner, Gleason, Watts and Chan matters, the Company maintains D&O liability insurance coverage, with a company retention of $500,000. The D&O liability insurance coverage provides insurance coverage to both the Company and the Directors and Officers for covered defense and indemnification. Through December 31, 2018, the Company recorded a cumulative charge of $500,000, representing the insurance carrier retention requirement. The insurance carrier has provided notice that it has reserved certain rights, and through the date of the filing of this Quarterly Report on Form 10-Q, the Company may incur additional costs related to these matters, the amounts of which are not able to be determined at this time.

Typenex Medical, LLC v. Akers Biosciences, Inc., JAMS Ref. No. 1450005929

On November 15, 2018, Typenex Medical LLC (“Typenex”), a telemarketing entity with whom the Company had entered into a marketing and commission agreement dated September 30, 2016 (the “Marketing Contract”), filed an arbitration against the Company before JAMS ADR (the “Arbitration”), and an arbiter was appointed to the Arbitration on December 14, 2018. In the Arbitration, Typenex stated that was seeking “at least” $220,500 based on the allegation that the Marketing Contract entitles Typenex to a commission on sales of certain of the Company’s heparin-related products in the period two years from the Marketing Contract’s expiration, and in the alternative, Typenex was seeking relief for breach of the implied covenant of good faith and fair dealing, and/or unjust enrichment.

On July 19, 2019, the Company and Typenex executed a settlement agreement. Pursuant to the settlement agreement, the Company agreed to pay Typenex $50,000 in cash and to issue 40,000 shares of the Company’s common stock. As of June 30, 2019, $66,800 is included in accrued expenses within the condensed consolidated balance sheets for this settlement.

NovoTek Therapeutics Inc. and NovoTek Pharmaceuticals Limited v. Akers Biosciences, Inc.

On June 21, 2019, the Company received a complaint, filed by Novotek Therapeutics Inc., and Novotek Pharmaceuticals Limited (collectively, “Novotek”), Beijing-based entities, in the United States District Court for the District of New Jersey, alleging, among other things, breach of contract. Novotek is seeking, among other things, damages in the amount of $1,551,562, plus interest, disbursements and attorneys’ fees. The Company vigorously disputes the allegations in the complaint and has retained counsel to defend it. The Company is not yet able to determine the amount of the Company’s exposure, if any.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 8 – Commitments and Contingencies, continued

Litigation and Settlements, continued

Neelima Varma v. Akers Biosciences, Inc. and St. David’s Healthcare Partnership, L.P., LLP CAUSE NO: D-1-GN-19-004262

On July 25, 2019, the Company was notified that on July 23, 2019, a complaint was filed by Neelima Varma, against the Company and St. David’s Healthcare Partnership, L.P., LLP (“St. David’s”), in the district court of Travis County, Texas, alleging, among other things, negligence, gross negligence and strict product liability, breach of express warranty, breach of implied warranty and fraudulent misrepresentation and omission, with respect to a medical device which the Company had sold through one its distributors to St. David’s. Ms. Varma is seeking aggregate monetary relief from the Company and St. David’s in excess of $1,000,000. The Company carries product liability insurance. The insurance carrier has provided notice that it has reserved certain rights. The Company and its insurance carrier will contest this complaint vigorously. The Company believes that its product liability insurance coverage will be adequate to cover the potential exposure for this matter.

Douglas Carrara v. Akers Biosciences, Inc., John Does 1-10, and XYZ Corp. 1-10, Docket No. ESX-L-5272-19 (N.J. Super. Ct., Essex County):

Douglas Carrara, a former executive, has sued the Company over the termination of his employment. The executive seeks contractual severance pay in the amount of $200,000. The executive asserts that the termination was without cause within the meaning of his employment agreement, which provides for severance of one year’s salary in the event of termination without cause. The executive also seeks indemnification for approximately $8,000 in attorneys’ fees that he contends he incurred in regard to company business. With regard to both claims, the executive seeks to recover his attorneys’ fees under a fee-shifting provision in his employment agreement.

The Company’s answer to the complaint is due August 28, 2019. With respect to this matter, the Company believes that the ultimate liability from the resolution of this matter will not be material to the Company’s condensed consolidated financial statements.

Other

A former executive has threatened to sue the Company over the termination of the executive’s employment. The executive contends that the termination was in retaliation for complaints to the employer protected under the California whistleblower protection laws. The executive also contends that the Company failed to pay a bonus in violation of an employment contract. The Company’s management and legal counsel believes it is too early to determine the probable outcome of this matter.

The Company intends to establish a rigorous defense of all claims. All legal fees were expensed as and when incurred.

Note 9 – Related Parties

CEO and Interim CFO

Effective on October 5, 2018, the Board appointed Howard R. Yeaton, to serve as the Chief Executive Officer and interim Chief Financial Officer of the Company. Mr. Yeaton is the managing principal of FCS and the Company’s relationship with FCS shall continue, with FCS continuing to provide accounting services to the Company. FCS is considered to be a related party. During the three and six months ended June 30, 2019, the Company incurred costs of $0 and $23,506 with FCS in connection with these services. As of June 30, 2019, the Company owed FCS $52,913 which is included in trade and other payables on the Condensed Consolidated Balance Sheet.

AKERS BIOSCIENCES, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 10 – Revenue Information

Revenue by product lines was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Product Line	2019		2018		2019		2018
MicroParticle Catalyzed Biosensor (“MPC”)	$	65,344	$	106,680	$	88,664	$	125,630
Particle ImmunoFiltration Assay (“PIFA”)		304,658		356,082		880,973		616,066
Rapid Enzymatic Assay (“REA”)		85,000		45,100		85,000		55,000
Other		9,511		18,739		21,997		32,380
Total Revenue	$	464,513	$	526,601	$	1,076,634	$	829,076

The total revenue by geographic area determined based on the location of the customers was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Geographic Region	2019		2018		2019		2018
United States	$	447,013	$	462,383	$	1,059,134	$	757,116
Rest of World		17,500		64,218		17,500		71,960
Total Revenue	$	464,513	$	526,601	$	1,076,634	$	829,076

The Company had long-lived assets totaling $13,097 and $14,294 located in the People’s Republic of China and $278,791 and $312,573 located in the United States as of June 30, 2019 and December 31, 2018, respectively.

Note 11 – Employee Benefit Plan

The Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the “401(k) Plan”). Under the 401(k) Plan, the Company matches 100% up to a 3% contribution, and 50% over a 3% contribution, up to a maximum of 5%.

During the three months ended June 30, 2019 and 2018, the Company made matching contributions to the 401(k) Plan of $7,425 and $15,314, respectively and $16,888 and $29,116 for the six months ended June 30, 2019 and 2018, respectively.

Note 12 – Subsequent Event

Pursuant to an unsecured promissory note dated July 4, 2019, on July 25, 2019 the Company advanced $100,000 to a company in the hemp related industry with which the Company has been considering for a potential business transaction. The loan bears interest at a rate of 8% per annum, and is payable in full on October 2, 2019.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q and other reports filed by Akers Biosciences, Inc. (“Akers”, “Akers Bio”, “we” or the “Company”) from time to time with the SEC (collectively, the “Filings”) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used in the Filings, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting any available alternative would not produce a materially different result. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.

Overview

Akers Bio develops, manufactures, and supplies rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a timely and cost-efficient manner. Akers believes it has advanced the science of diagnostics through the development of several proprietary platform technologies.

All of Akers’ rapid, single-use tests are performed in vitro (outside the body) and are designed to enhance patient well-being and reduce the cost of healthcare. The Company’s current product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin, for cholesterol screening and for on- and off-the-job alcohol safety initiatives.

Akers believes that low-cost, single-use testing not only saves time and money, but allows for more frequent, near-patient testing which may save lives. We believe that our FDA-cleared rapid diagnostic tests help facilitate targeted diagnoses and real-time treatment.

Key Events, Management’s Plans and Basis of Presentation

Board’s Evaluation of Strategic Alternatives

On November 7, 2018, the Company announced that its Board of Directors had initiated a process to evaluate strategic alternatives to maximize shareholder value. This process is ongoing and is considering a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities. On November 19, 2018, the Company further announced that in its evaluation of strategic alternatives it will consider a range of potential strategic alternatives including, but not limited to, business combinations in sectors different than that currently engaged in, including cannabis and hemp related industries. There can be no assurance that the exploration of strategic alternatives will result in any transaction or other alternative.

Further to the Company’s pursuit of strategic alternatives, pursuant to an unsecured promissory note dated July 4, 2019, on July 25, 2019 the Company advanced $100,000 to a company in the hemp related industry with which the Company has been considering a potential business transaction. The loan bears interest at a rate of 8% per annum, and is payable in full on October 2, 2019.

Delisting from AIM

On December 19, 2018, the Company announced its intent to delist from the AIM Market of the London Stock Exchange. The Company believed that due to the relatively low liquidity in the Company’s common stock, reaming listed does not merit the ongoing costs and regulatory complexities associated with maintaining the AIM listing. On March 5, 2019, the Company held a special meeting of shareholders who then voted in favor of the Company delisting from the AIM Market. The delisting took effect on March 29, 2019.

Board Compensation

On March 29, 2019, the Compensation Committee of the Board of Directors approved Board compensation, payable as follows. Lump sum of $64,000 to be paid to each of directors Schreiber and White and a lump sum of $56,000 to be paid to director Silverman. Such amounts were paid during April 2019. Beginning for the month of April 2019, each director shall be paid $8,000 per month. Further, each director was granted 124,827 Restricted Stock Units (“RSUs”). Such RSUs shall vest on January 1, 2020, with vesting accelerated upon a change of control. Such RSUs shall be settled in shares of common stock, including on a net of tax basis, at the discretion of the holder.

NASDAQ Notice

By way of a letter dated May 10, 2019, the Listing Qualifications Department of NASDAQ advised the Company that it did not comply with NASDAQ Listing Rule 5550(a)(2) for continued listing, because the Company’s Common stock did not meet NASDAQ’s minimum $1.00 bid price requirement (the “Price Requirement”). The Company intends to monitor the closing bid price of the Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Price Requirement under the NASDAQ Listing Rules.

Summary of Statements of Operations for the Three Months Ended June 30, 2019 and 2018

Revenue

Akers’ revenue for the three months ended June 30, 2019 totaled $464,513, a 12% decrease from the same period in 2018. The table below summarizes our revenue by product line for the three months ended June 30, 2019 and 2018, as well as the percentage of change year-over-year:

	For the Three Months Ended June 30,
Product Lines	2019		2018		Percent Change

Particle ImmunoFiltration Assay (“PIFA”)	$	304,658	$	356,082		(14	)%
MicroParticle Catalyzed Biosensor (“MPC”)		65,344		106,680		(39	)%
Rapid Enzymatic Assay (“REA”)		85,000		45,100		88	%
Other		9,511		18,739		(49	)%
Total Revenue	$	464,513	$	526,601		(12	)%

Revenue from the Company’s PIFA products decreased 14% to $304,658 (2018: $356,082) during the three months ended June 30, 2019, as compared to the same period of 2018. The decrease in the 2019 quarter was principally attributable to a larger new customer order in 2018 which was not repeated in the 2019 quarter.

Aker’s largest U.S. distribution partners are Cardinal Health and Thermo Fisher Scientific. Domestic net sales for the three months ended June 30, 2019 for these two distributors accounted for $284,714 of the total PIFA related product revenue as compared to $185,263 for the same period of 2018.

The Company’s MPC product sales decreased by 39% to $65,344 (2018: $106,680) during the three months ended June 30, 2019. The sales decrease was principally attributable to the loss of a customer who had a large order in the 2018 quarter.

The Company’s REA products generated $85,000 (2018: $45,100) during the three months ended June 30, 2019. The increase was attributable to a significant order by a large customer.

Other revenue decreased to $9,511 (2018: $18,739) during the three months ended June 30, 2019 due to a decline in shipping/handling revenue. The category is made up principally of shipping and handling charges.

Gross Margin

The Company’s gross profit percentage improved to 53% (2018: 42%), and the gross margin improved to $244,649 (2018: $223,775) for the three months ended June 30, 2019, principally due to our focus on a more narrowed and higher margin product lineup. Furthermore, improvements in gross margin were attributable to cost reductions, including reduced headcount.

Cost of sales for the three months ended June 30, 2019 decreased to $219,864 (2018: $302,826) on account of lower revenues, as well as on account of the aforementioned production efficiencies and headcount reductions.

Administrative Expenses

Administrative expenses for the three months ended June 30, 2019, totaled $981,309, which was a 37% decrease as compared to $1,565,602 for the three months ended June 30, 2018.

The table below summarizes our administrative expenses for the three months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Three Months Ended June 30,				Percent Change
Description	2019		2018
Personnel Costs	$	169,960	$	192,792		(12	)%
Professional Service Costs		345,282		927,812		(63	)%
Stock Market & Investor Relations Costs		63,407		145,771		(57	)%
Other Administrative Costs		402,660		299,227		35	%
Total Administrative Expense	$	981,309	$	1,565,602		(37	)%

Personnel expenses decreased by 12% for the three months ended June 30, 2019 as compared to the same period of 2018 on account of a reduction in administrative headcount to four as of June 30, 2019, as compared to five as of June 30, 2018.

Professional service costs decreased 63% for the three months ended June 30, 2019 as compared to the same period of 2018, principally on account of reduced legal fees ($368,405 (2018: $605,175)) and a decrease in accounting and audit expenses (($25,160) (2018: $236,042)). The higher costs in 2018 were principally attributable to the investigation and restatement of the financial statements, and certain litigation defense costs.

Stock market and investor fees decreased 57% for the three months ended June 30, 2019. The decrease in these fees was principally associated with the Company having delisted from the London Stock Exchange during the first quarter of 2019, and thereafter avoiding the costs associated with a presence on the London Stock Exchange.

Other administrative expenses increased by 35%, principally attributable to increased business insurance costs, $128,411 (2018: $52,053) and Director’s fees and expenses $190,478 (2018: $600).

Sales and Marketing Expenses

Sales and marketing expenses for the three months ended June 30, 2019 totaled $14,139 which was a 97% decrease compared to $469,469 for the three months ended June 30, 2018.

The table below summarizes our sales and marketing expenses for the three months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Three Months Ended June 30,
Description	2019			2018		Percent Change
Personnel Costs	$	(114	)	$	266,889		(100	)%
Professional Service Costs		10,712			69,065		(84	)%
Royalties and Outside Commission Costs		(2,709	)		69,983		(104	)%
Other Sales and Marketing Costs		6,250			63,532		(90	)%
Total Sales and Marketing Expenses	$	14,139		$	469,469		(97	)%

During the first quarter of 2019, as part of our cost savings measures, we eliminated the personnel within the sales and marketing departments, including employees, consultants and third party related representatives.

Personnel expenses decreased by 100% for the three months ended June 30, 2019 as compared to the same period of 2018 on account of the reduction in the Sales and Marketing headcount to zero as of June 30, 2019, as compared to five as of June 30, 2018.

Professional service costs decreased 84% for the three months ended June 30, 2019, as compared to the same period of 2018, principally on account of reductions in the services provided by third party vendors.

Royalties and outside commission costs decreased by 104%, on account of the elimination of independent sales representatives (“ISRs).

Other Sales and Marketing Costs declined to $6,250 (2018: $63,532) principally due to the reductions in travel and entertainment for the sales and marketing personnel.

Compliance, Research and Development Expenses

Compliance, research and development expenses for the three months ended June 30, 2019 totaled $60,909, which was a 76% decrease as compared to $259,124 for the three months ended June 30, 2018.

The table below summarizes our compliance, research and development expenses for the three months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Three Months Ended June 30,
Description	2019		2018		Percent Change
Personnel Costs	$	59,237	$	176,202		(66	)%
Clinical Trial Costs		-		575		(100	)%
Professional Service Costs		1,299		48,620		(97	)%
Other Compliance, Research and Development Costs		373		33,727		(99	)%
Total Compliance, Research and Development Expenses	$	60,909	$	259,124		(76	)%

During the second half of 2018, we eliminated the research and development functions of the company in connection with focusing the business on current products and reducing costs.

Personnel expenses decreased by 66% for the three months ended June 30, 2019 as compared to the same period of 2018 due to a reduction in the headcount to three as of June 30, 2019, as compared to ten as of June 30, 2018. With these staff reductions, we eliminated the research & development functions, with the remaining personnel maintaining regulatory and quality assurance (compliance) functions.

Professional service costs, principally third party engineering costs, declined by 97% for the three months ended June 30, 2019, as compared to the same period of 2018, principally on account of the elimination of research & development activities.

Other compliance, research and development costs declined by 99%, for the three months ended June 30, 2019, as compared to the same period of 2018, principally on account of reduction in research and development activities, as discussed above.

Other Income and Expense

Other income, net of expense, for the three months ended June 30, 2019 totaled $26,819 as compared to $45,744 for the three months ended June 30, 2018.

The table below summarizes our other income and expenses for the three months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Three Months Ended June 30,
Description	2019			2018			Percent Change
Currency Translation Loss	$	(219	)	$	(3,029	)		93	%
Realized Gains on Investments		(543	)		(4,400	)		88	%
Interest and Dividend Income		27,581			53,173			(48	)%
Total Other Income, Net of Expenses	$	26,819		$	45,744			(41	)%

Summary of Statements of Operations for the Six Months Ended June 30, 2019 and 2018

Revenue

Akers’ revenue for the six months ended June 30, 2019 totaled $1,076,634, a 30% increase from the same period in 2018. The table below summarizes our revenue by product line for the six months ended June 30, 2019 and 2018, as well as the percentage of change year-over-year:

	For the Six Months Ended June 30,
Product Lines	2019		2018		Percent Change

Particle ImmunoFiltration Assay (“PIFA”)	$	880,973	$	616,066		43	%
MicroParticle Catalyzed Biosensor (“MPC”)		88,664		125,630		(29	)%
Rapid Enzymatic Assay (“REA”)		85,000		55,000		55	%
Other		21,997		32,380		(32	)%
Total Revenue	$	1,076,634	$	829,076		30	%

Revenue from the Company’s PIFA products increased 43% to $880,973 (2018: $616,066) during the six months ended June 30, 2019, as compared to the same period of 2018. The increase was attributable to product supply issues encountered in the first two quarters of 2018 that were not experienced in the 2019 periods.

Aker’s largest U.S. distribution partners are Cardinal Health and Thermo Fisher Scientific. Domestic net sales for the six months ended June 30, 2019 for these two distributors accounted for $831,989 of the total PIFA related product revenue as compared to $394,734 for the same period of 2018.

The Company’s MPC product sales decreased by 29% to $88,664 (2018: $125,630) during the six months ended June 30, 2019. The sales decrease was principally attributable to the loss of a customer who had a large order in the 2018 quarter.

The Company’s REA products generated $85,000 (2018: $55,000) during the six months ended June 30, 2019, principally on account of a large order by a customer during the 2019 period.

Other revenue decreased to $21,997 (2018: $32,380) during the six months ended June 30, 2019 due to a decline in shipping/handling revenue. The category is made up principally of shipping and handling charges.

Gross Margin

The Company’s gross profit percentage improved to 57% (2018: 28%), and the gross margin improved to $610,833 (2018: $228,750) for the six months ended June 30, 2019, principally due to our focus on a more narrowed and higher margin product lineup. Furthermore, improvements in gross margin were attributable to cost reductions, including reduced headcount, as well as a higher level of revenues against production fixed costs, such as for rent and supervisory personnel.

Cost of sales for the six months ended June 30, 2019 decreased to $465,801 (2018: $600,326) on account of the aforementioned production efficiencies and headcount reductions.

Administrative Expenses

Administrative expenses for the six months ended June 30, 2019, totaled $1,964,265, which was a 21% decrease as compared to $2,481,134 for the six months ended June 30, 2018.

The table below summarizes our administrative expenses for the six months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Six Months Ended June 30,				Percent Change
Description	2019		2018
Personnel Costs	$	377,999	$	499,727		(24	)%
Professional Service Costs		575,165		1,231,750		(53	)%
Stock Market & Investor Relations Costs		277,961		259,937		7	%
Other Administrative Costs		733,140		489,720		50	%
Total Administrative Expense	$	1,964,265	$	2,481,134		(21	)%

Personnel expenses decreased by 24% for the six months ended June 30, 2019 as compared to the same period of 2018 on account of a reduction in administrative headcount to four as of June 30, 2019, as compared to five as of June 30, 2018.

Professional service costs decreased 53% for the six months ended June 30, 2019 as compared to the same period of 2018, principally on account of reduced legal fees ($518,727 (2018: $883,451)) and accounting and audit expenses ($14,881 (2018: $236,042)). The higher costs in 2018 were principally attributable to the investigation and restatement of the financial statements, and certain litigation defense costs.

Stock market and investor fees increased 7% for the six months ended June 30, 2019. The increase in these fees was principally associated with the costs incurred in connection with the withdrawal from the London Stock Exchange.

Other administrative expenses increased by 50%, principally attributable to business insurance costs, $255,548 (2018: $95,752) and Director’s fees and expenses, including stock-based compensation, of $293,384 (2018: $1,818).

Sales and Marketing Expenses

Sales and marketing expenses for the six months ended June 30, 2019 totaled $163,979 which was an 83% decrease compared to $969,620 for the six months ended June 30, 2018.

The table below summarizes our sales and marketing expenses for the six months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Six Months Ended June 30,
Description	2019		2018		Percent Change
Personnel Costs	$	65,717	$	588,598		(89	)%
Professional Service Costs		33,103		140,623		(76	)%
Royalties and Outside Commission Costs		40,750		97,838		(58	)%
Other Sales and Marketing Costs		24,409		142,561		(83	)%
Total Sales and Marketing Expenses	$	163,979	$	969,620		(83	)%

Personnel expenses decreased by 89% for the six months ended June 30, 2019 as compared to the same period of 2018 on account of the reduction in the Sales and Marketing headcount to zero as of June 30, 2019, as compared to five as of June 30, 2018.

Professional service costs decreased by 76% for the six months ended June 30, 2019, as compared to the same period of 2018 primarily on account of reductions in marketing and sales related consultants.

Royalties and outside commission costs decreased by 58%, principally on account of ISR costs incurred for approximately two months in 2019 as compared to six months in the 2018 period. An evaluation of the ISR program determined it to be ineffective and, as a result, all ISR’s agreements were terminated effective February 19, 2019.

Other Sales and Marketing Costs declined to $24,409 (2018: $142,561) principally due to the reductions in travel and entertainment for the sales and marketing personnel.

Compliance, Research and Development Expenses

Compliance, research and development expenses for the six months ended June 30, 2019 totaled $149,300, which was a 79% decrease as compared to $699,094 for the six months ended June 30, 2018.

The table below summarizes our compliance, research and development expenses for the six months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Six Months Ended June 30,
Description	2019		2018		Percent Change
Personnel Costs	$	130,403	$	475,415		(73	)%
Clinical Trial Costs		-		1,480		(100	)%
Professional Service Costs		10,043		137,896		(93	)%
Other Compliance, Research and Development Costs		8,854		84,303		(89	)%
Total Compliance, Research and Development Expenses	$	149,300	$	699,094		(79	)%

During the second half of 2018, we eliminated the research and development functions of the company in connection with focusing the business on current products and reducing costs.

Personnel expenses decreased by 73% for the six months ended June 30, 2019 as compared to the same period of 2018 due to a reduction in the headcount to three as of June 30, 2019, as compared to ten as of June 30, 2018. These staff reductions eliminated the research & development functions, with the remaining personnel maintaining regulatory and quality assurance (compliance) functions.

Professional service costs, principally third party engineering costs, declined by 93% for the six months ended June 30, 2019, as compared to the same period of 2018, principally on account of the elimination of research & development activities.

Other compliance, research and development costs declined by 89%, for the six months ended June 30, 2019, as compared to the same period of 2018, principally on account of reduction in research and development activities, as discussed above.

Other Income and Expense

Other income, net of expense, for the six months ended June 30, 2019 totaled $49,866 as compared to $79,208 for the six months ended June 30, 2018.

The table below summarizes our other income and expenses for the six months ended June 30, 2019 and 2018 as well as the percentage of change year-over-year:

	For the Six Months Ended June 30,
Description	2019			2018			Percent Change
Currency Translation Loss	$	(4,878	)	$	(5,905	)		17	%
Investment Loss		(4,258	)		(4,401	)		3	%
Interest and Dividend Income		59,002			89,514			(34	)%
Total Other Income, Net of Expenses	$	49,866		$	79,208			(37	)%

Liquidity and Capital Resources

On November 7, 2018, we announced that our Board of Directors had initiated a process to evaluate strategic alternatives to maximize shareholder value. This process is considering a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities. On November 19, 2018, we further announced that we will consider a range of potential strategic alternatives including, but not limited to, business combinations in alternative sectors including cannabis and hemp related industries. There can be no assurance that these explorations of strategic alternatives will result in any transaction or other alternative.

We expect to continue to incur losses from operations for the near-term and these losses could be significant. Furthermore, our investments in pursuit of strategic alternatives will require cash, including, for example, loans and investments, as discussed earlier with respect to the $100,000 loan. We are closely monitoring our cash balances, cash needs and expense levels. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that might result in the possible inability of the Company to continue as a going concern.

Capital expenditures for the six months ended June 30, 2019 were $0 (2018: $37,698).

Operating Activities

Our net cash consumed by operating activities totaled $1,610,352 during the six months ended June 30, 2019. Cash was consumed by the loss of $1,711,849 reduced by non-cash adjustments principally consisting of $3,514 for accrued interest on marketable securities, $34,979 for depreciation and amortization of non-current assets, $4,247 for the allowance of doubtful accounts, $4,258 for loss on sales of securities and $144,828 for share based compensation. For the six months ended June 30, 2019, within changes of assets and liabilities, cash provided consisted of a decrease in inventories of $41,026, a decrease in prepaid expenses of $305,531, a decrease in deposits and other receivables of $9,347, a decrease in other assets of $4,330, off-set by an increase in trade receivables of $94,781 and a decrease in trade and other payables of $355,782.

Our net cash consumed by operating activities totaled $3,817,892 during the six months ended June 30, 2018. Cash was consumed by the loss of $3,927,444 reduced by non-cash adjustments of $112,903 for depreciation and amortization of non-current assets, $3,469 for the amortization of deferred compensation, $32,283 for the reserve for obsolete inventory, $97,000 for the reserve for doubtful accounts, $5,454 for share based compensation to employees, $5,175 for share based compensation to directors and $12,545 for share based compensation to non-employees less $16,332 for accrued income on marketable securities. For the six months ended June 30, 2018, primarily related to routine changes in operating activities, cash consumed consisted of an increase in deposits and other receivables of $43,941, an increase in inventories of $99,220, an increase in prepaid expenses of $521,676, off-set by a decrease in trade receivables of $455,048 and an increase in trade and other payables of $66,844.

Investing Activities

The Company’s net cash provided by investing totaled $1,292,130, as compared to net cash used in investing of $2,999,777 during the six months ended June 30, 2019 and 2018, respectively. Net cash provided by investing activities for the six months ended June 30, 2019 consisted of proceeds from the sale of marketable securities of $1,354,646. During the six months ended June 30, 2018, investing activities consisted of proceeds from the sale of marketable securities of $2,306,675, off-set by purchases of marketable securities of $5,268,754.

Financing Activities

The Company’s net cash provided by financing activities in 2019 was $0 (2018: $7,155,200). Net cash provided during the 2018 period reflected principally net proceeds from the public and private placements of common and Series B preferred stock and the exercise of warrants for Common Stock, contributing $7,155,200.

Liquidity

The Company has experienced recurring losses and negative cash flows from operations. Management’s strategic plans include the following:

	●	evaluating strategic alternatives to maximize shareholder value, including the consideration of a range of potential strategic alternatives including, but not limited to, business combinations and

	●	Continuing to monitor and implement cost control initiatives to conserve cash.

At June 30, 2019, Akers had cash of $363,533 (including restricted cash of $115,094) and marketable securities of $4,020,498, working capital of $3,631,911, shareholders’ equity of $4,314,134 and an accumulated deficit of $117,406,730. In order to execute on our long-term strategy, including being able to execute upon our pursuit of potential strategic alternatives including but not limited to business combinations, we expect to need to raise additional funds through equity offerings, debt financing or other means. The Company may also issue equity or a portion of the purchase price for acquisitions may be in equity. There are no assurances that we will be able to produce such funds on acceptable terms or at all.

Critical Accounting Policies

See accounting policies in Note 2 of the condensed consolidated financial statements included in Part I, Item 1 of this report.

Off-Balance Sheet Arrangements

We have no significant known off balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We do not hold any derivative instruments and do not engage in any hedging activities.

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in paragraph (e) of Rules 13a-15 and 15d-15 under the Exchange Act) designed to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified under the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosures. As required by paragraph (b) of Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer (our principal executive officer and principal financial officer) carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2019. Based on this evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2019.

(b) Changes in Internal Control over Financial Reporting

During the six months ended June 30, 2019, material changes in internal control over financial reporting included the implementation of enhanced monthly inventory control and reconciliation procedures including conducting inventory test counts.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we are a party to litigation and subject to claims incident to the ordinary course of business. Future litigation may be necessary to defend ourselves and our customers by determining the scope, enforceability and validity of third party proprietary rights or to establish our proprietary rights.

Faulkner v. Akers Biosciences, Inc., No. 2:18-cv-10521 (D.N.J.) and Gleason v. Akers Biosciences, Inc., No. 2:18-cv-10805 (D.N.J.)

Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.)

Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.)

Watts and Chan Matters – Potential Resolution

Faulkner, Gleason, Watts and Chan Matters

Typenex Medical, LLC v. Akers Biosciences, Inc., JAMS Ref. No. 1450005929

NovoTek Therapeutics Inc. and NovoTek Pharmaceuticals Limited v. Akers Biosciences, Inc.

Neelima Varma v. Akers Biosciences, Inc. and St. David’s Healthcare Partnership, L.P., LLP CAUSE NO: D-1-GN-19-004262

On July 25, 2019, the Company was notified that on July 23, 2019, a complaint was filed by Neelima Varma, against the Company and St. David’s Healthcare Partnership, L.P., LLP (“St. David’s”), in the district court of Travis County, Texas, alleging, among other things, negligence, gross negligence and strict product liability, breach of express warranty, breach of implied warranty and fraudulent misrepresentation and omission, with respect to a medical device which the Company had sold through one its distributors to St. David’s. Ms. Varma is seeking aggregate monetary relief from the Company and St. David’s in excess of $1,000,000. The Company carries product liability insurance. The insurance carrier has provided notice that it has reserved certain rights. The Company and its insurance carrier will contest this complaint vigorously. We believe that our product liability insurance coverage will be adequate to cover the potential exposure for this matter.

Douglas Carrara v. Akers Biosciences, Inc., John Does 1-10, and XYZ Corp. 1-10, Docket No. ESX-L-5272-19 (N.J. Super. Ct., Essex County):

Dispute with a Former Executive

The Company intends to establish a rigorous defense of all claims. All legal fees were expensed as and when incurred.

With the exception of the foregoing, we are not currently involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public Board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company, threatened against or affecting our Company or our Common Stock, in which an adverse decision could have a material adverse effect.

Item 1A. Risk Factors

There are no additional risk factors other than those discussed in our Annual Report Form 10-K filed on April 1, 2019.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of the Company’s equity securities during the quarter ended June 30, 2019, other than those previously reported in a Current Report on Form 8-K.

Item 3. Defaults Upon Senior Securities

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of the Company.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information.

Not applicable.

Item 6. Exhibits.

31.1		Certification by the Principal Executive Officer and Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). *

32.1		Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AKERS BIOSCIENCES, INC.

Date: August 14, 2019	By:	/s/ Howard Yeaton
	Name:	Howard Yeaton
	Title:	Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Howard Yeaton, certify that:

	1.	I have reviewed this Form 10-Q of Akers Biosciences, Inc.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2019	By:	/s/ Howard Yeaton
		Howard Yeaton
		Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
		Akers Biosciences, Inc.

EX-32.1 3 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Akers Biosciences, Inc. (the “Company”), on Form 10-Q for the period ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission on the date hereof, the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: August 14, 2019	By:	/s/ Howard Yeaton
		Howard Yeaton
		Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
		Akers Biosciences, Inc.

EX-101.INS 4 aker-20190630.xml XBRL INSTANCE FILE 0001321834 2019-01-01 2019-06-30 0001321834 2017-12-31 0001321834 us-gaap:TradeAccountsReceivableMember 2018-01-01 2018-12-31 0001321834 AKER:PeoplesRepublicOfChinaMember 2018-12-31 0001321834 country:US 2018-01-01 2018-06-30 0001321834 country:US 2019-01-01 2019-06-30 0001321834 AKER:RestofWorldMember 2018-01-01 2018-06-30 0001321834 AKER:RestofWorldMember 2019-01-01 2019-06-30 0001321834 AKER:MicroParticleCatalyzedBiosensorMPCMember 2019-01-01 2019-06-30 0001321834 AKER:MicroParticleCatalyzedBiosensorMPCMember 2018-01-01 2018-06-30 0001321834 AKER:ParticleImmunoFiltrationAssayPIFAMember 2019-01-01 2019-06-30 0001321834 AKER:ParticleImmunoFiltrationAssayPIFAMember 2018-01-01 2018-06-30 0001321834 AKER:OtherMember 2018-01-01 2018-06-30 0001321834 AKER:OtherMember 2019-01-01 2019-06-30 0001321834 us-gaap:CommonStockMember 2017-12-31 0001321834 AKER:DeferredCompensationMember 2017-12-31 0001321834 us-gaap:RetainedEarningsMember 2017-12-31 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001321834 country:US 2018-12-31 0001321834 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001321834 AKER:RapidEnzymaticAssayREAMember 2019-01-01 2019-06-30 0001321834 AKER:RapidEnzymaticAssayREAMember 2018-01-01 2018-06-30 0001321834 us-gaap:PreferredStockMember 2017-12-31 0001321834 2018-12-31 0001321834 us-gaap:PreferredStockMember 2018-12-31 0001321834 us-gaap:CommonStockMember 2018-12-31 0001321834 AKER:DeferredCompensationMember 2018-12-31 0001321834 us-gaap:RetainedEarningsMember 2018-12-31 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001321834 AKER:WarrantsMember 2018-12-31 0001321834 AKER:SettlementAgreementMember 2018-12-31 0001321834 AKER:SettlementAgreementMember 2018-01-01 2018-12-31 0001321834 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001321834 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerOneMember 2018-01-01 2018-12-31 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerTwoMember 2018-01-01 2018-12-31 0001321834 us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerOneMember 2018-12-31 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerTwoMember 2018-12-31 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerOneMember 2019-01-01 2019-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerTwoMember 2019-01-01 2019-06-30 0001321834 AKER:TradePayablesMember AKER:ThreeVendorsMember 2019-01-01 2019-06-30 0001321834 us-gaap:ShippingAndHandlingMember 2019-01-01 2019-06-30 0001321834 us-gaap:ShippingAndHandlingMember 2018-01-01 2018-06-30 0001321834 2018-01-01 2018-06-30 0001321834 2018-06-30 0001321834 AKER:ThorofareLeaseMember 2013-01-05 2013-01-07 0001321834 AKER:ThorofareLeaseMember 2013-01-07 0001321834 AKER:EquipmentOperatingLeaseMember 2019-06-30 0001321834 AKER:PitmanLeaseMember 2014-09-22 2014-09-29 0001321834 AKER:PitmanLeaseMember 2014-09-24 0001321834 AKER:MarketingContractMember 2018-11-13 2018-11-15 0001321834 AKER:MarketingContractMember srt:MinimumMember 2018-11-13 2018-11-15 0001321834 AKER:ThorofareLeaseMember 2019-06-30 0001321834 AKER:FourZeroOneKPlanMatchesFiftyPercentMember 2019-01-01 2019-06-30 0001321834 AKER:FourZeroOneKPlanMaximumFivePercentMember 2019-01-01 2019-06-30 0001321834 2019-08-09 0001321834 2019-06-30 0001321834 us-gaap:PreferredStockMember 2019-06-30 0001321834 us-gaap:CommonStockMember 2019-06-30 0001321834 AKER:DeferredCompensationMember 2019-06-30 0001321834 us-gaap:RetainedEarningsMember 2019-06-30 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001321834 2018-03-31 0001321834 us-gaap:FairValueInputsLevel1Member 2019-06-30 0001321834 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001321834 us-gaap:FairValueInputsLevel3Member 2019-06-30 0001321834 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001321834 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001321834 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001321834 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001321834 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001321834 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001321834 srt:MaximumMember 2019-01-01 2019-06-30 0001321834 srt:MinimumMember 2019-01-01 2019-06-30 0001321834 us-gaap:SalesRevenueNetMember 2018-01-01 2018-06-30 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerOneMember 2019-01-01 2019-06-30 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerTwoMember 2019-01-01 2019-06-30 0001321834 us-gaap:TradeAccountsReceivableMember 2019-01-01 2019-06-30 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerOneMember 2019-06-30 0001321834 us-gaap:TradeAccountsReceivableMember AKER:CustomerTwoMember 2019-06-30 0001321834 us-gaap:CostOfGoodsTotalMember AKER:SupplierOneMember 2018-04-01 2018-06-30 0001321834 us-gaap:CostOfGoodsTotalMember AKER:SupplierTwoMember 2018-04-01 2018-06-30 0001321834 us-gaap:CostOfGoodsTotalMember 2019-01-01 2019-06-30 0001321834 AKER:OneSupplierMember us-gaap:CostOfGoodsTotalMember srt:MinimumMember 2018-01-01 2018-06-30 0001321834 us-gaap:CostOfGoodsTotalMember 2018-04-01 2018-06-30 0001321834 AKER:HowardRYeatonMember AKER:EmploymentAgreementMember 2019-01-01 2019-06-30 0001321834 AKER:FinancialConsultingStrategiesLLCMember 2019-01-01 2019-06-30 0001321834 AKER:FinancialConsultingStrategiesLLCMember 2019-06-30 0001321834 AKER:ThorofareLeaseMember 2019-01-01 2019-06-30 0001321834 AKER:ThorofareLeaseMember 2018-01-01 2018-06-30 0001321834 AKER:PitmanLeaseMember 2019-01-01 2019-06-30 0001321834 AKER:PitmanLeaseMember 2018-01-01 2018-06-30 0001321834 AKER:PitmanLeaseMember 2019-06-30 0001321834 AKER:SettlementAgreementMember AKER:ChubeWorkxMember 2019-01-01 2019-06-30 0001321834 AKER:SettlementAgreementMember AKER:ChubeWorkxMember us-gaap:RoyaltyMember 2019-01-01 2019-06-30 0001321834 AKER:SettlementAgreementMember AKER:ChubeWorkxMember 2019-06-30 0001321834 AKER:ChubeWorkxMember 2019-01-01 2019-06-30 0001321834 AKER:SettlementAgreementMember 2019-03-07 2019-03-08 0001321834 AKER:SettlementAgreementMember AKER:WattsActionMember 2019-01-13 2019-01-14 0001321834 AKER:TwoThousandThirteenStockIncentivePlanMember 2014-01-23 0001321834 AKER:AmendedPlanMember us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001321834 AKER:TwoThousandAndSeventeenStockIncentivePlanMember 2017-08-07 0001321834 AKER:TwoThousandAndSeventeenStockIncentivePlanMember us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001321834 AKER:TwoThousandAndEighteenStockIncentivePlanMember 2018-12-07 0001321834 AKER:TwoThousandAndEighteenStockIncentivePlanMember us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001321834 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2019-03-29 0001321834 AKER:WarrantsMember 2019-01-01 2019-06-30 0001321834 AKER:WarrantsMember 2019-06-30 0001321834 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001321834 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001321834 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001321834 AKER:PatentsTrademarksAndCustomerListsMember 2019-06-30 0001321834 AKER:AmendedPlanMember 2019-06-30 0001321834 AKER:TwoThousandAndSeventeenStockIncentivePlanMember 2019-06-30 0001321834 AKER:TwoThousandAndEighteenStockIncentivePlanMember 2019-06-30 0001321834 us-gaap:PreferredStockMember 2018-06-30 0001321834 us-gaap:CommonStockMember 2018-06-30 0001321834 AKER:DeferredCompensationMember 2018-06-30 0001321834 us-gaap:RetainedEarningsMember 2018-06-30 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001321834 AKER:HowardRYeatonMember AKER:EmploymentAgreementMember 2018-12-31 0001321834 2019-04-01 2019-06-30 0001321834 2018-04-01 2018-06-30 0001321834 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001321834 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0001321834 us-gaap:PreferredStockMember 2018-04-01 2018-06-30 0001321834 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001321834 us-gaap:PreferredStockMember 2019-03-31 0001321834 us-gaap:PreferredStockMember 2018-03-31 0001321834 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001321834 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001321834 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001321834 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001321834 us-gaap:CommonStockMember 2019-03-31 0001321834 us-gaap:CommonStockMember 2018-03-31 0001321834 AKER:DeferredCompensationMember 2019-01-01 2019-03-31 0001321834 AKER:DeferredCompensationMember 2018-01-01 2018-03-31 0001321834 AKER:DeferredCompensationMember 2018-04-01 2018-06-30 0001321834 AKER:DeferredCompensationMember 2019-04-01 2019-06-30 0001321834 AKER:DeferredCompensationMember 2019-03-31 0001321834 AKER:DeferredCompensationMember 2018-03-31 0001321834 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001321834 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001321834 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001321834 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001321834 us-gaap:RetainedEarningsMember 2019-03-31 0001321834 us-gaap:RetainedEarningsMember 2018-03-31 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001321834 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001321834 2019-01-01 2019-03-31 0001321834 2018-01-01 2018-03-31 0001321834 2019-03-31 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerOneMember 2019-04-01 2019-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerTwoMember 2019-04-01 2019-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerThreeMember 2019-04-01 2019-06-30 0001321834 us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerOneMember 2018-04-01 2018-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerTwoMember 2018-04-01 2018-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerThreeMember 2018-04-01 2018-06-30 0001321834 us-gaap:SalesRevenueNetMember 2018-04-01 2018-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerOneMember 2018-01-01 2018-06-30 0001321834 us-gaap:SalesRevenueNetMember AKER:CustomerTwoMember 2018-01-01 2018-06-30 0001321834 us-gaap:CostOfGoodsTotalMember AKER:SupplierOneMember 2019-04-01 2019-06-30 0001321834 us-gaap:CostOfGoodsTotalMember AKER:SupplierTwoMember 2019-04-01 2019-06-30 0001321834 us-gaap:CostOfGoodsTotalMember 2019-04-01 2019-06-30 0001321834 AKER:TradePayablesMember AKER:VendorOneMember 2019-06-30 0001321834 AKER:TradePayablesMember AKER:VendorTwoMember 2019-06-30 0001321834 AKER:TradePayablesMember AKER:VendorThreeMember 2019-06-30 0001321834 us-gaap:ShippingAndHandlingMember 2018-04-01 2018-06-30 0001321834 us-gaap:ShippingAndHandlingMember 2019-04-01 2019-06-30 0001321834 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001321834 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001321834 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001321834 AKER:HowardRYeatonMember AKER:EmploymentAgreementMember 2019-04-01 2019-06-30 0001321834 AKER:HowardRYeatonMember AKER:EmploymentAgreementMember 2018-04-01 2018-06-30 0001321834 AKER:HowardRYeatonMember AKER:EmploymentAgreementMember 2018-01-01 2018-06-30 0001321834 AKER:ThorofareLeaseMember 2019-04-01 2019-06-30 0001321834 AKER:ThorofareLeaseMember 2018-04-01 2018-06-30 0001321834 AKER:RamseyLeaseMember 2019-01-01 2019-06-30 0001321834 AKER:RamseyLeaseMember 2019-06-30 0001321834 AKER:RamseyLeaseMember 2019-04-01 2019-06-30 0001321834 AKER:RamseyLeaseMember 2018-04-01 2018-06-30 0001321834 AKER:RamseyLeaseMember 2018-01-01 2018-06-30 0001321834 AKER:PitmanLeaseMember 2019-04-01 2019-06-30 0001321834 AKER:PitmanLeaseMember 2018-04-01 2018-06-30 0001321834 AKER:SettlementAgreementMember us-gaap:SubsequentEventMember 2019-07-23 2019-07-24 0001321834 AKER:SettlementAgreementMember us-gaap:SubsequentEventMember 2019-07-18 2019-07-19 0001321834 AKER:SettlementAgreementMember us-gaap:SubsequentEventMember 2019-07-19 0001321834 AKER:NovoTekTherapeuticsIncAndNovoTekPharmaceuticalsLimitedMember 2019-01-20 2019-01-21 0001321834 AKER:NeelimaVarmaAndStDavidsHealthCarePartnershipLPMember 2019-01-24 2019-01-25 0001321834 AKER:FinancialConsultingStrategiesLLCMember 2019-04-01 2019-06-30 0001321834 AKER:PeoplesRepublicOfChinaMember 2019-06-30 0001321834 country:US 2019-06-30 0001321834 AKER:MicroParticleCatalyzedBiosensorMPCMember 2019-04-01 2019-06-30 0001321834 AKER:ParticleImmunoFiltrationAssayPIFAMember 2019-04-01 2019-06-30 0001321834 AKER:RapidEnzymaticAssayREAMember 2019-04-01 2019-06-30 0001321834 AKER:OtherMember 2019-04-01 2019-06-30 0001321834 AKER:MicroParticleCatalyzedBiosensorMPCMember 2018-04-01 2018-06-30 0001321834 AKER:ParticleImmunoFiltrationAssayPIFAMember 2018-04-01 2018-06-30 0001321834 AKER:RapidEnzymaticAssayREAMember 2018-04-01 2018-06-30 0001321834 AKER:OtherMember 2018-04-01 2018-06-30 0001321834 country:US 2019-04-01 2019-06-30 0001321834 country:US 2018-04-01 2018-06-30 0001321834 AKER:RestofWorldMember 2019-04-01 2019-06-30 0001321834 AKER:RestofWorldMember 2018-04-01 2018-06-30 0001321834 us-gaap:SubsequentEventMember AKER:UnsecuredPromissoryNoteMember 2019-07-25 0001321834 us-gaap:SubsequentEventMember AKER:UnsecuredPromissoryNoteMember 2019-07-23 2019-07-25 0001321834 AKER:StDavidsHealthCarePartnershipLPMember 2019-01-25 0001321834 AKER:DouglasCarraraMember AKER:SeverencePayMember 2019-01-01 2019-06-30 0001321834 AKER:DouglasCarraraMember AKER:AttorneysFeesMember 2019-01-01 2019-06-30 0001321834 us-gaap:SubsequentEventMember 2019-08-09 0001321834 2019-05-10 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure AKER:Breathalyzers false 2019-06-30 Q2 --12-31 Non-accelerated Filer

-1711849

-3927444

-794891

-2067453

-916958

-1859991

-2067453

-794891

-916958

-1859991

10-Q Akers Biosciences, Inc.

7552853

110647169

-3469

-104845847

1755000

5833753

121554547

-115694881

-25913

10794809

4314134

121699375

-117406730

21489

11417245

119580543

-108773291

-12443

121574327

118139926

-116611839

-106705838

3430

-16843

4965918

0001321834

163979

969620

14139

469469

7155200

610833

228750

244649

223775

-1761715

-4006652

-821710

-2113197

20004

85554

10002

42777

149300

699094

60909

259124

-49866

-79208

-26819

-45744

4878

5905

219

3029

-1711849

-3927444

-794891

-2067453

-0.14

-0.38

-0.06

-0.18

12492115

10293569

12500923

11656788

-355782

66844

-305531

521676

-41026

99220

-9347

43941

94781

-455048

5454

2742

3469

34979

112903

-3514 16332

1354646

2306675

62516

5268754

37698

181755

248439

18059

4400

29343

-16843

4400

18059

29343

-16843

6570

15874

5175

6570

15874

5175

0.73

0.59

0.14

0.78

0.45

0.44

0.70

0.66

0.53

0.23

0.76

0.13

0.11

0.50

0.24

0.42

0.20

0.19

0.81

0.33

0.27

0.12

0.72

0.49

0.17

0.00

0.66

0.76

27579

64937

15660

37993

32283

41849

7477

542761

404094

711181

686386

635565

479457

1304240

1025696

54804

58771

11760

23250

27082

686578

741875

32160

106468

1500519

10502

4064

30.41

25.04

33.79

25.04

P1Y5M5D

P0Y P0Y P6M29D P0Y P1Y6M

P1Y6M

1964265

2481134

981309

1565602

14294

312573

13097

278791

59750

5272998

4020498

9347

585267

544241

444435

169591

6670128

5249629

12002

7672

1137125

682223

7807253

5931852

1973500

1617718

121554547

121699375

7807253

5931852

50000000

500000000

12482708

12508958

12482708

12508958

P90D P30D

-25913

21489

-115694881

-117406730

1227172

816093

1755000

47402 -12443

17.42

7.46

103750

168750

1875000

124827

71590

62282

374481

606835

605848

83456

68481

23179

1000

66800

2 3 2 2 3

465801

21997

13641

600326

219864

302826

18739

9511

1711849

3927444

794891

2067453

2489282

1441479

25250

4064

1416229

2110737

374481

6438

-1610352

-3817892

1292130

-2999777

7155200

500000

115094

1076634

757116

1059134

71960

17500

88664

125630

880973

616066

32380

21997

85000

55000

829076

464513

526601

65344

304658

85000

9511

106680

356082

45100

18739

447013

462383

17500

64218

2019

5272998

4020498

3990000

true true false

75000

23.72

less than one year

Note 1 – Organization and Description of Business   Akers Biosciences, Inc. (“Akers”), is a New Jersey corporation. These condensed consolidated financial statements include two wholly owned subsidiaries, Akers Acquisition Sub, Inc. and Bout Time Marketing Corporation, (together, the “Company”). All material intercompany transactions have been eliminated in consolidation.   On November 7, 2018, the Company announced its intention to explore strategic alternatives in order to maximize shareholder value. As announced, this process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities.   Furthermore, the Company has undertaken steps to reduce its expenses, including reducing the number of personnel, reducing its office footprint, eliminating services from non-critical vendors and has withdrawn its shares from registration on the AIM exchange in the United Kingdom.   The Company’s medical device business has as its current focus the production and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s principal products are a rapid test detecting the antibody causing an allergic reaction to Heparin, breath alcohol detectors used for health and safety and a consumer product used to screen for levels of cholesterols.

Note 2 – Significant Accounting Policies   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basis of Presentation</td></tr> </table>   The Condensed Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP).   Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed. As such, the information included in these financial statements should be read in conjunction with the audited financial statements as of and for the years ended December 31, 2018 and 2017 included in the Company’s 2018 Form 10-K, as filed on April 1, 2019. In the opinion of the management, these condensed consolidated financial statements include all adjustments, consisting of only normal recurring nature, necessary for a fair statement of the financial position of the Company as of June 30, 2019 and its results of operations and cash flows for the three and six months ended June 30, 2019 and 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2019.   The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(b)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Use of Estimates and Judgments</td></tr> </table>   The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for revenue recognition, allowances for doubtful accounts, inventory write-downs, impairment of intangible assets and valuation of share-based payments.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(c)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional and Presentation Currency</td></tr> </table>   These condensed consolidated financial statements are presented in U.S. Dollars, which is the Company’s functional currency. All financial information presented in U.S. Dollars has been rounded to the nearest dollar. Foreign Currency Transaction Gains or Losses, resulting from cash balances denominated in Foreign Currencies, are recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(d)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Comprehensive Income (Loss)</td></tr> </table>   The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income (loss). Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(e)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cash and Cash Equivalents</td></tr> </table>   The Company considers all highly liquid investments, which include short-term bank deposits (up to 3 months from date of deposit) that are not restricted as to withdrawal date or use, to be cash equivalents.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(f)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restricted Cash </td></tr> </table>   At June 30, 2019, restricted cash included in non-current assets on the Company’s consolidated balance sheet was $115,094 representing cash in trust for the purpose of funding legal fees for certain litigations.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(g)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value of Financial Instruments</td></tr> </table>   The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities.   The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 1.25in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs to the valuation methodology include:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 1.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">quoted prices for similar assets or liabilities in active markets;</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">quoted prices for identical or similar assets or liabilities in inactive markets;</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">inputs other than quoted prices that are observable for the asset or liability;</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">inputs that are derived principally from or corroborated by observable market data by correlation or other means</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 1.25in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td></tr> </table>   The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.   Following is a description of the valuation methodologies used for assets measured at fair value as of June 30, 2019 and December 31, 2018.   U.S. Agency Securities: Valued using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt">Marketable securities at June 30, 2019</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">                -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">4,020,498</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">                      -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities at December 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,272,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Marketable securities include U.S. agency securities, which are classified as available for sale. The securities are valued at fair market value. Maturities of the securities are less than one year. Unrealized gains and losses relating to the available for sale investment securities were recorded in the Condensed Consolidated Statement of Changes in Shareholders’ Equity as comprehensive (loss) income. These amounts were $18,059 and $47,402 in unrealized gain for the three and six months ended June 30, 2019 and a decrease of $4,401 and an increase of $12,443 in unrealized loss for the three and six months ended June 30, 2018, respectively.   Gains and losses resulting from the sales of marketable securities were a loss of $543 and $4,400 for the three months ended June 30, 2019 and 2018, and a loss of $4,258 and $4,401 for the six months ended June 30, 2019 and 2018, respectively.   Proceeds from the sale of marketable securities in the three and six months ended June 30, 2019 were $502,126 and $1,354,646, respectively and in the three and six months ended June 30, 2018 were $2,004,580 and $2,306,675, respectively.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(h)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade Receivables and Allowance for Doubtful Accounts </td></tr> </table>   The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature.   The normal credit terms extended to customers ranges between 30 and 90 days. Credit terms longer than these may be extended after considering the credit worthiness of the customers and the business requirements. The Company reviews all receivables that exceed terms and establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade and other receivables. A considerable amount of judgment is required in assessing the amount of allowance. The Company considers the historical level of credit losses, makes judgments about the credit worthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future.   As of June 30, 2019 and December 31, 2018, allowances for doubtful accounts for trade receivables were $605,848 and $606,835. Bad debt expenses for trade receivables were $0 and $125,500 for the three months ended June 30, 2019 and 2018, respectively and $4,247 and $125,500 for the six months ended June 30, 2019 and 2018, respectively.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Concentrations </td></tr> </table>   Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks is in excess of the FDIC insurance limit. The Company has not experienced any loss as a result of these cash deposits. These cash balances are maintained with two banks.   Major Customers   For the three months ended June 30, 2019, three customers generated 42%, 20%, and 19% or 81% in the aggregate, of the Company’s revenue. For the six months ended June 30, 2019, two customers generated 44% and 34%, or 78% in the aggregate, of the Company’s revenue.   For the three months ended June 30, 2018, three customers generated 33%, 27%, and 12%, or 72% in aggregate, of the Company’s revenue. For the six months ended June 30, 2018, two customers generated 49% and 17%, or 66% in the aggregate, of the Company’s revenue.   Two customers accounted for 53% and 23%, or 76% in the aggregate, of gross trade receivables, before accounting for allowance for doubtful accounts, as of June 30, 2019. As of June 30, 2019, the Company had $458,902 and $201,330 in trade receivables, respectively, from these customers. These concentrations make the Company vulnerable to a near-term severe impact should these relationships be terminated. The largest of these customer balances was fully reserved as of June 30, 2019, and on June 21, 2019, this customer filed suit against the Company (see note 7).   Two customers accounted for 59% and 14%, or 73% in the aggregate, of gross trade receivables, before accounting for allowance for doubtful accounts, as of December 31, 2018. As of December 31, 2018, the Company had $458,902 and $111,037 in trade receivables, respectively, from these customers. These concentrations make the Company vulnerable to a near-term severe impact should these relationships be terminated. The largest of these customer balances was fully reserved as of December 31, 2018, and on June 21, 2019, this customer filed suit against the Company (see note 7).   To limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition.   Major Suppliers   For the three months ended June 30, 2019, two suppliers accounted for 66% and 10%, or 76%, in the aggregate, of the Company’s purchases. For the six months ended June 30, 2019, one supplier accounted for 50%, of the Company’s purchases.   For the three months ended June 30, 2018, two suppliers accounted for 13% and 11%, or 24% in the aggregate, of the Company’s purchases. For the six months ended June 30, 2018, no supplier accounted for 10% or more of the Company’s purchases.   Three vendors accounted for 70% in the aggregate, of trade payables as of June 30, 2019. As of June 30, 2019, the Company had $180,114, $123,000, and $116,206 in trade payables, respectively, to these vendors.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(j)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Property, Plant and Equipment</td></tr> </table>   Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset.   Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized within “other income” in the Condensed Consolidated Statement of Operations and Comprehensive Loss.   Depreciation is recognized in profit and loss on the accelerated basis over the estimated useful lives of the property, plant and equipment. Leased assets are depreciated over the shorter of the lease term or their useful lives.   Depreciation expense totaled $9,542 and $13,675 for the three months ended June 30, 2019 and 2018, respectively and $14,975 and $27,350 for the six months ended June 30, 2019 and 2018, respectively.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(k)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Intangible Assets</td></tr> </table>   The Company’s long-lived intangible assets, other than goodwill, are assessed for impairment when events or circumstances indicate there may be an impairment. These assets were initially recorded at their estimated fair value at the time of acquisition and assets not acquired in acquisitions were recorded at historical cost. However, if their estimated fair value is less than the carrying amount, other intangible assets with indefinite lives are reduced to their estimated fair value through an impairment charge to our condensed consolidated statements of operations and comprehensive loss.   Intangible assets as of June 30, 2019 and December 31, 2018 were $223,407 and $243,411, respectively. Intangible assets at June 30, 2019 consisted of patents, trademarks and customer lists of $3,897,635 net of accumulated amortization and impairment of $3,674,228.   Amortization is recognized on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use. Amortization expense was $10,002 and $42,777 for the three months ended June 30, 2019 and 2018, respectively and $20,004 and $85,553 for the six months ended June 30, 2019 and 2018, respectively.   The following is an annual schedule of approximate future amortization of the Company’s intangible assets:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 73%; text-align: left">2019 (six months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">20,004</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,371</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">223,407</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(l)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue Recognition </td></tr> </table>   Beginning on January 1, 2019, the Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle:   Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the company satisfies a performance obligation   The Company does not have any significant contracts with customers requiring performance beyond delivery. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control of the product transfers to our customer, which generally occurs upon delivery to the customer but can also occur when goods are shipped by the Company, depending on the shipment terms of the contract. The Company’s performance obligations are satisfied at that time.   The Company uses the most likely amount approach to determine the variable consideration of the transaction price in order to account for the contractual rebates and incentives that are estimated and adjusted for over time. The Company provides for rebates to its distributors. The Company had accrued for rebates and incentives of $1,000 and $23,179, as of June 30, 2019 and December 31, 2018. Accounts receivable will be reduced when the rebates are applied by the customer. The Company recognized $7,679 and $6,350 during the three months ended June 30, 2019 and 2018 and $16,377 and $43,894 for the six months ended June 30, 2019 and 2018 for rebates, which is included as a reduction of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(m)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Income Taxes</td></tr> </table>   The Company utilizes an asset and liability approach for financial accounting and reporting for income taxes. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse.   The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management’s opinion, adequate provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.   Tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for “unrecognized tax benefits” is recorded for any tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of June 30, 2019 and December 31, 2018, no liability for unrecognized tax benefits was required to be reported.   There is no income tax benefit for the losses for the three and six months ended June 30, 2019 and 2018 since management has determined that the realization of the net deferred assets is not assured and has created a valuation allowance for the entire amount of such tax benefits.   The Company’s policy for recording interest and penalties associated with tax audits is to record such items as a component of general and administrative expense. There were no amounts accrued for penalties and interest for the three and six months ended June 30, 2019 and 2018. The Company does not expect its uncertain tax position to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(o)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shipping and Handling Fees and Costs </td></tr> </table>   The Company charges actual shipping costs plus a handling fee to customers, which amounted to $9,511 and $18,739 for the three months ended June 30, 2019 and 2018 and $21,997 and $32,380 for the six months ended June 30, 2019 and 2018, respectively. These fees are classified as part of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as product cost of sales, which amounted to $15,660 and $37,993 for the three months ended June 30, 2019 and 2018, respectively and $27,579 and $64,937 for the six months ended June 30, 2019 and 2018, respectively.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(p)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basic and Diluted Earnings per Share of Common Stock</td></tr> </table>   Basic earnings per common share is based on the weighted average number of shares outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. Potential common shares that would have the effect of increasing diluted earnings per share are considered anti-dilutive.   The calculation of basic and diluted loss per share for the three months ended June 30, 2019 and 2018 was based on the net loss of $794,891 and $2,067,453, respectively and $1,711,849 and $3,927,444 for the six months ended June 30, 2019 and 2018, respectively. The basic and diluted weighted average number of common shares outstanding for the three months ended June 30, 2019 and 2018 was 12,500,923 and 11,656,788, respectively and 12,492,115 and 10,293,569 for the six months ended June 30, 2019 and 2018, respectively.   Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period.   The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three and Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Stock Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">4,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">25,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">374,481</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,110,737</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,416,229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total potentially dilutive shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,489,282</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,441,479</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(q)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recently Issued Accounting Pronouncements</td></tr> </table>   Recently Issued Accounting Pronouncements Adopted   As the Company is an emerging growth company (“EGC”), it has elected to adopt recently issued accounting pronouncements based on effective dates applicable to other than public business entities. The Company is expected to lose its EGC status on December 31, 2019 as it is the last day of the fiscal year following the fifth anniversary of the effective date of its registration statement on January 23, 2014.   In May 2014 and April 2016, the FASB issued ASU No. 2014-09 and ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, FASB issued ASU 2015-14 which deferred the effective date of Update 2014-09 to annual reporting periods beginning after December 15, 2018 for entities other than public business entities, and to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period for public business entities.   The Company has elected to apply the modified retrospective method and the impact was determined to be immaterial on the condensed consolidated financial statements. Accordingly, the new revenue standard was applied prospectively in our condensed consolidated financial statements from January 1, 2019 forward and reported financial information for historical comparable periods will not be revised and will continue to be reported under the accounting standards in effect during those historical periods.   The Company has performed an analysis and identified its revenues and costs that are within the scope of the new guidance. The Company has determined that its methods of recognizing revenues will not be significantly impacted by the new guidance.   In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is effective for public business entities, certain not-for-profit entities, and certain employee benefit plans for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, ASU 2018-07 is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company early adopted ASC 2018-07 effective January 1, 2019. There was no material impact on the Company’s condensed consolidated financial statements upon this adoption.   In July 2018, the FASB issued ASU No. 2018-09, Codification Improvements, to makes changes to a variety of topics to clarify, correct errors in, or make minor improvements to the Accounting Standards Codification. Certain items of the amendments in ASU 2018-09 will be effective for the Company in annual periods beginning after December 15, 2018. The adoption of ASU 2018-09 did not have a material impact on the Company’s condensed consolidated financial statements.   Recently Issued Accounting Pronouncements Not Adopted   In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842) (“ASU-2016-02”), which requires an entity to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor, and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the effect this guidance will have on its condensed consolidated financial statements and related disclosure, and anticipates the guidance to result in increases in its assets and liabilities as most of its operating lease commitments will be subject to the new standard and recognized as right-of-use assets and lease liabilities.   In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments (“ASU-2016-13”). ASU 2016-13 affects loans, debt securities, trade receivables, and any other financial assets that have the contractual right to receive cash. The ASU requires an entity to recognize expected credit losses rather than incurred losses for financial assets. ASU 2016-13 is effective for the fiscal year beginning after December 15, 2019, including interim periods within that fiscal year. The Company is currently evaluating the effect this guidance will have on its condensed consolidated financial statements and related disclosures.

Note 4 – Inventories   Inventories are measured at the lower of cost or net realizable value. The cost of inventories is based on the weighted-average principle, and includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of manufactured inventories and work in progress, costs include an appropriate share of production overhead based on normal operating capacity.   Inventories consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Raw Materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">404,094</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">542,761</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Sub-Assemblies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">686,386</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">711,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finished Goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">479,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">635,565</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reserve for Obsolescence</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,025,696</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,304,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">544,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">585,267</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Obsolete inventory charged to cost of goods was $41,849 and $7,477, during the three months ended June 30, 2019 and 2018, and $45,946 and $28,987 during the six months ended June 30, 2019 and 2018, respectively.

Note 5 - Trade and Other Payables   Trade and other payables consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Trade Payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">741,875</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">686,578</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">816,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,227,172</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Deferred Compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,617,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,973,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   See also Note 9 for related party information.

Note 6 - Share-based Payments   Equity incentive Plans   2013 Stock Incentive Plan   On January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (“2013 Plan”). The 2013 Plan was amended by the Board on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides for the issuance of up to 103,750 shares of the Company’s common stock. As of June 30, 2019, grants of restricted stock and options to purchase 71,590 shares of Common Stock have been issued pursuant to the 2013 Plan, and 32,160 shares of Common Stock remain available for issuance.   2017 Stock Incentive Plan   On August 7, 2017, the shareholders approved and the Company adopted the 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan provides for the issuance of up to 168,750 shares of the Company’s common stock. As of June 30, 2019, grants of restricted stock and options to purchase 62,282 shares of Common Stock have been issued pursuant to the 2017 Plan, and 106,468 shares of Common Stock remain available for issuance.   2018 Stock Incentive Plan   On December 7, 2018, the shareholders approved and the Company adopted the 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the issuance of up to 1,875,000 shares of the Company’s common stock. As of June 30, 2019, grants of RSUs to purchase 374,481 shares of Common Stock have been issued pursuant to the 2018 Plan, and 1,500,519 shares of Common Stock remain available for issuance.   Stock Options   The following table summarizes the option activities for the six months ended June 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-weight: bold; font-style: italic">Balance at December 31, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">10,502</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">30.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">          -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,438</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Canceled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">1.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Exercisable as of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">1.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.45 for the Company’s common shares on June 30, 2019. As the closing stock price on June 30, 2019 is lower than the exercise price, there is no intrinsic value to disclose.   As of June 30, 2019, all of the Company’s outstanding stock options were fully vested and exercisable.   During the three months ended June 30, 2019 and 2018, the Company incurred stock option expenses totaling $0 and $2,742, respectively and $0 and $5,454 for the six months ended June 30, 2019 and 2018, respectively.   Restricted Stock Units   On March 29, 2019, the Compensation Committee of the Board of Directors approved the grant of 124,827 Restricted Stock Units (“RSU”) to each of the three directors. Each RSU had a grant date fair value of $0.97 which shall be amortized on a straight-line basis over the vesting period into administrative expenses within the Condensed Consolidated Statement of Operations and Comprehensive Loss. Such RSUs were granted under the 2018 Plan, and shall vest on January 1, 2020, with vesting accelerated upon a change of control. Upon vesting, such RSUs are settled with the issuance of common stock, including on a net of tax basis, at the discretion of the holder.   At June 30, 2019, the unamortized value of the RSU’s was $240,863. The unamortized amount will be expensed over the remaining period of six months. A summary of activity related to RSUs for the six months ended June 30, 2019 is presented below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Balance at December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; padding-left: 10pt">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">374,481</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.97</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Canceled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">374,481</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Exercisable as of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   During the three and six months ended June 30, 2019, the Company incurred RSU expense of $118,478 and $122,384, respectively.   Stock Warrants   The table below summarizes the warrant activity for the period ended June 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Remaining Contractual Term (years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; font-style: italic">Balance at December 31, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2,110,737</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">4.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">                -</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Canceled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,110,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Exercisable as of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,110,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.45 for the Company’s common shares on June 30, 2019. All warrants were vested on date of grant.

Note 7 – Equity   During the six months ended June 30, 2019, the Company issued 26,250 shares of Common Stock to Mr. Yeaton pursuant to his employment agreement. These shares had a fair value of $22,444 on the date of grant, of which $4,238 was recorded in trade and other payables in the consolidated balance sheet as of December 31, 2018 and $6,570 and $18,206 were recorded as expense in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2019 and 2018, respectively.

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify">(g)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value of Financial Instruments</td></tr> </table>   The Company’s financial instruments consist of cash and cash equivalents, marketable securities, receivables and trade and other payables. The carrying value of cash and cash equivalents, receivables and trade and other payables approximate their fair value because of their short maturities.   The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 1.25in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">Level 1</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Level 2</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs to the valuation methodology include:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 1.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 0.3in; font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">quoted prices for similar assets or liabilities in active markets;</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">quoted prices for identical or similar assets or liabilities in inactive markets;</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">inputs other than quoted prices that are observable for the asset or liability;</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">inputs that are derived principally from or corroborated by observable market data by correlation or other means</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 1.25in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">Level 3</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td></tr> </table>   The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.  Following is a description of the valuation methodologies used for assets measured at fair value as of June 30, 2019 and December 31, 2018.   U.S. Agency Securities: Valued using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt">Marketable securities at June 30, 2019</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">                -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">4,020,498</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">                      -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities at December 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,272,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Marketable securities include U.S. agency securities, which are classified as available for sale. The securities are valued at fair market value. Maturities of the securities are less than one year. Unrealized gains and losses relating to the available for sale investment securities were recorded in the Condensed Consolidated Statement of Changes in Shareholders’ Equity as comprehensive (loss) income. These amounts were $18,059 and $47,402 in unrealized gain for the three and six months ended June 30, 2019 and a decrease of $4,401 and an increase of $12,443 in unrealized loss for the three and six months ended June 30, 2018, respectively.   Gains and losses resulting from the sales of marketable securities were a loss of $543 and $4,400 for the three months ended June 30, 2019 and 2018, and a loss of $4,258 and $4,401 for the six months ended June 30, 2019 and 2018, respectively.   Proceeds from the sale of marketable securities in the three and six months ended June 30, 2019 were $502,126 and $1,354,646, respectively and in the three and six months ended June 30, 2018 were $2,004,580 and $2,306,675, respectively.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three and Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Stock Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">4,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">25,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>RSUs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">374,481</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,110,737</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,416,229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total potentially dilutive shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,489,282</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,441,479</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Inventories consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Raw Materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">404,094</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">542,761</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Sub-Assemblies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">686,386</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">711,181</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Finished Goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">479,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">635,565</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Reserve for Obsolescence</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,025,696</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,304,240</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">544,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">585,267</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following table summarizes the option activities for the six months ended June 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Term (years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-weight: bold; font-style: italic">Balance at December 31, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">10,502</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">30.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">17.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">1.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">          -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,438</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23.72</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Canceled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">1.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Exercisable as of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,064</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">25.04</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7.46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">1.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Revenue by product lines was as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Product Line</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">MicroParticle Catalyzed Biosensor (“MPC”)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">65,344</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">106,680</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">88,664</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125,630</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Particle ImmunoFiltration Assay (“PIFA”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">304,658</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">880,973</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">616,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rapid Enzymatic Assay (“REA”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,511</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,739</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,997</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,380</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">464,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">526,601</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,076,634</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The total revenue by geographic area determined based on the location of the customers was as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Geographic Region</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">United States</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">447,013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">462,383</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,059,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">757,116</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,218</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,960</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">464,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">526,601</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,076,634</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

176326

458902

111037

266860

458902

201330

180114

123000

116206

1973500

1617718

4238

26250

298256 267569

4258

4401

543

4400

4247

97000

-318222

337531

438432

681755

775963

363533

Note 10 – Revenue Information   Revenue by product lines was as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Product Line</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">MicroParticle Catalyzed Biosensor (“MPC”)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">65,344</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">106,680</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">88,664</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">125,630</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Particle ImmunoFiltration Assay (“PIFA”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">304,658</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">356,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">880,973</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">616,066</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rapid Enzymatic Assay (“REA”)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">55,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,511</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,739</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,997</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,380</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">464,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">526,601</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,076,634</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The total revenue by geographic area determined based on the location of the customers was as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six Months Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Geographic Region</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">United States</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">447,013</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">462,383</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,059,134</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">757,116</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,218</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,960</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total Revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">464,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">526,601</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,076,634</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">829,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company had long-lived assets totaling $13,097 and $14,294 located in the People’s Republic of China and $278,791 and $312,573 located in the United States as of June 30, 2019 and December 31, 2018, respectively.

This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; padding-bottom: 2.5pt">Marketable securities at June 30, 2019</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">                -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">4,020,498</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</td><td style="width: 16%; border-bottom: Black 2.5pt double; text-align: right">                      -</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities at December 31, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,272,998</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

243411

223407

3897635

Note 8 – Commitments and Contingencies   Lease Commitments   The Company leases its facility in West Deptford, New Jersey under an operating lease (“Thorofare Lease”) with annual rentals of $132,000 plus common area maintenance (CAM) charges. The lease, which took effect on January 1, 2008, reduced the CAM charges allowing the Company to reach their own agreements with utilities and other maintenance providers. On January 7, 2013, the Company extended its lease agreement for a term of 7 years, expiring December 31, 2019. Rent expense for the Thorofare Lease, including related CAM charges for the three months ended June 30, 2019 and 2018 totaled $40,955 and $40,928, respectively and $82,320 and $83,144 for the six months ended June 30, 2019 and 2018, respectively. The Company entered into a 24-month lease for a satellite office located in Ramsey, New Jersey (“Ramsey Lease”) with annual rents of $25,980 plus common area maintenance (CAM) charges. The lease took effect on June 1, 2017 and ran through May 31, 2019. Rent expenses for the Ramsey Lease, including related CAM charges totaled $6,495 and $6,495 for the three months ended June 30, 2019 and 2018, respectively, and $12,990 and $12,990 for the six months ended June 30, 2019 and 2018, respectively. The Company entered into a 29-month lease for warehouse space located in Pitman, New Jersey (“Pitman Lease”) with annual rents of $40,839. The lease took effect on August 1, 2017 and runs through December 31, 2019. Rent expenses for the Pitman Lease totaled $10,210 and $9,913 for the three months ended June 30, 2019 and 2018, and $20,420 and $19,825 for the six months ended June 30, 2019 and 2018, respectively. A security deposit of $4,950 is included in other assets on the Condensed Consolidated Balance Sheet.   The Company entered into a 60-month operating lease for equipment with annual rentals of $6,156 on September 29, 2014. The lease commenced on October 21, 2014 upon the delivery of the equipment.   The schedule of lease commitments is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Thorofare</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Pitman</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Equipment</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Next 6 Months</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">19,824</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,078</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">88,902</td><td style="width: 1%; text-align: left"> </td></tr> </table>   ChubeWorkx   On August 17, 2016, pursuant to a Settlement Agreement (the “Settlement Agreement”) with ChubeWorkx Guernsey Limited (“ChubeWorkx”), which settled all pending claims between the Company and ChubeWorkx. Specifically, the Company and ChubeWorkx agreed to voluntarily dismiss (i) the action in the United States Federal Court, District of New Jersey brought by the Company against ChubeWorkx for outstanding amounts due to the Company under a promissory note and (ii) the action in The High Court of Justice, Queen’s Bench Division Commercial Court, Royal Courts of Justice, United Kingdom brought by ChubeWorkx against the Company arising from an exclusive licensing agreement between ChubeWorkx and the Company (“Licensing Agreement”).   In return for the Company regaining the full rights to sell breath technology products, under the terms of the Settlement Agreement, ChubeWorkx is entitled to receive a royalty of 5% of the Company’s gross revenues (the “ChubeWorkx Royalty”) until ChubeWorkx has earned an aggregate $5,000,000, after which point ChubeWorkx will no longer be entitled to receive any royalties from the Company and the Company shall have no further obligation to ChubeWorkx. The Settlement Agreement further allows the Company to retain 50% of the ChubeWorkx Royalty until the full $549,609 cash component of the monies owed by ChubeWorkx to the Company as described above has been satisfied. The Company recorded royalty expenses of $23,520 and $27,082 for the three months ended June 30, 2019 and 2018, and $54,804 and $58,771 for the six months ended June 30, 2019 and 2018, respectively, which are included in sales and marketing expenses on the Condensed Consolidated Statement of Operations and Comprehensive Loss. As of June 30, 2019, the Company owed ChubeWorkx royalties of $11,760 which is included in trade and other payables within the condensed consolidated balance sheet.   Other terms of the Settlement included: 1) the pledge as security of all earned but unpaid royalties by the Company to ChubeWorkx all Company assets, worthy to satisfy its obligations, including all inventory and receivables, with the exception of (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; 2) the pledge as security of the settlement sum which remains unpaid by the Company to ChubeWorkx all Company (i) distribution contracts of the Company or any of its affiliates, (ii) customer lists, (iii) manufacturing processes (including all intellectual property required to use those processes and exploit products made thereby), and (iv) all equipment required to perform said manufacturing processes and other equipment; and 3) the grant of voting proxy by ChubeWorkx to the Company which allows the Company to vote ChubeWorkx’s shares for corporate formalities under certain conditions.   The pledged assets are only at risk in the event that the Company cannot satisfy any outstanding royalty payment obligations subject to various cure periods and/or through a restructuring and/or liquidation under the United States Bankruptcy laws of the Company in favor of payment of said obligation.   Litigation and Settlements   Faulkner v. Akers Biosciences, Inc., No. 2:18-cv-10521 (D.N.J.) and Gleason v. Akers Biosciences, Inc., No. 2:18-cv-10805 (D.N.J.)   On June 13, 2018, Plaintiff Tim Faulkner filed a class action complaint alleging securities violations against Akers Biosciences, Inc. (“Akers”), John J. Gormally, and Gary M. Rauch (“Individual Defendants”) (together with Akers, “Defendants”) on behalf of all persons and entities who purchased publicly traded Akers securities from May 15, 2017 through June 5, 2018 (the “Faulkner Action”). The complaint alleges violations of Section 10(b) of the Exchange Act and Rule 10b-5 against all Defendants, and violations of Section 20(a) of the Exchange Act against the Individual Defendants. In particular, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose in its first, second, and third quarter 2017 10-Qs and its 2017 10-K that: (1) Akers was improperly recognizing revenue for the fiscal year ended December 31, 2017; and, (2) Akers had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses. On June 20, 2018, Plaintiff David Gleason filed a class action complaint under the caption Gleason v. Akers Biosciences, Inc., No. 2:18-cv-10805 (D.N.J.) based on the same allegations and causes of action (the “Gleason Action”). On November 21, 2018, the Faulkner and Gleason Actions were consolidated under the Faulkner Action docket. The parties conducted a mediation on January 10, 2019 and agreed to a settlement in principle disposing of the consolidated action as to all Defendants, including the Individual Defendants. On March 8, 2019, the parties signed a settlement agreement, subject to approval by the Court, whereby the Company agreed to pay $2,250,000 in exchange for full releases and discharge of all claims against the Company. On the same day, Lead Plaintiffs filed a motion for preliminary approval of the settlement and to establish notice procedures. On July 3, 2019, the Court granted the motion for preliminary approval and scheduled a final settlement hearing for November 8, 2019. On or about July 24, 2019, the Company’s D&O insurer sent the settlement payment of $2,250,000 to the settlement agent for the class.   Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.)   On November 9, 2018, Plaintiff Cale Watts filed a verified shareholder derivative complaint alleging violations of the Securities Exchange Act of 1934, breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on alleged material weaknesses in controls, management, and documentation (the “Watts Action”). On January 14, 2019, the parties reached an agreement in principle to settle the Watts Action that included corporate reforms and an attorneys’ fees payment of $200,000. The parties finalized a Stipulation of Settlement on March 4, 2019. On March 22, 2019, Plaintiffs filed a motion seeking (a) preliminary approval of the proposed Settlement, (b) approval of the proposed form and method of providing notice of the Settlement, and (c) scheduling a hearing for final approval of the settlement (the “Motion for Preliminary Approval”). On April 1, 2019, Tiffany Chan, Jasmine Henderson, and Don Danesh Wijesekera (the “Proposed Intervenors”) filed an Opposition to the Motion for Preliminary Approval, and a Motion to Intervene and Stay Proceedings (“Motion to Intervene and Stay”). Defendants’ Opposition to the Motion to Intervene and Stay is due August 20, 2019, and its Reply in further support of the Motion for Preliminary Approval is due August 27, 2019. The Motion for Preliminary Approval and the Motion to Intervene and Stay are currently returnable on September 3, 2019.   Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.)   On February 7, 2019, Tiffany Chan, Jasmine Henderson, and Don Danesh filed a verified shareholder derivative complaint alleging violations of Section 14(a) of the Exchange Act and SEC Rule 14a-9, breach of fiduciary duty, unjust enrichment, and waste of corporate assets based on the same circumstances as the Watts Action. The Chan Action further alleges that the Company should not have settled the Watts Action because the Watts Action plaintiffs lacked standing and the settlement would cause irreparable harm to the Company and its shareholders. On April 4, 2019, the Court entered the parties’ stipulation and consent order to extend Defendants’ time to answer, move, or otherwise respond to the Complaint until 20 days after the Court (a) decides the Motion for Preliminary Approval of the Watts Settlement, (b) decides the Motion in Opposition to the Watts Settlement, (c) decides the Motion to Intervene and Stay in the Watts Action, and/or (d) stays the Watts Action.   Watts and Chan Matters – Potential Resolution   On August 12, 2019, counsel for all parties in the Watts Action and the Chan Action informed the Watts Court that they had agreed in principle to a resolution of both the Watts and Chan Actions, and expected to have finalized paperwork for the Court’s review and approval within 30-45 days. The parties have a follow-up call scheduled with the Court for October 3, 2019.   Faulkner, Gleason, Watts and Chan Matters   With respect to the Faulkner, Gleason, Watts and Chan matters, the Company maintains D&O liability insurance coverage, with a company retention of $500,000. The D&O liability insurance coverage provides insurance coverage to both the Company and the Directors and Officers for covered defense and indemnification. Through December 31, 2018, the Company recorded a cumulative charge of $500,000, representing the insurance carrier retention requirement. The insurance carrier has provided notice that it has reserved certain rights, and through the date of the filing of this Quarterly Report on Form 10-Q, the Company may incur additional costs related to these matters, the amounts of which are not able to be determined at this time.   Typenex Medical, LLC v. Akers Biosciences, Inc., JAMS Ref. No. 1450005929   On November 15, 2018, Typenex Medical LLC (“Typenex”), a telemarketing entity with whom the Company had entered into a marketing and commission agreement dated September 30, 2016 (the “Marketing Contract”), filed an arbitration against the Company before JAMS ADR (the “Arbitration”), and an arbiter was appointed to the Arbitration on December 14, 2018. In the Arbitration, Typenex stated that was seeking “at least” $220,500 based on the allegation that the Marketing Contract entitles Typenex to a commission on sales of certain of the Company’s heparin-related products in the period two years from the Marketing Contract’s expiration, and in the alternative, Typenex was seeking relief for breach of the implied covenant of good faith and fair dealing, and/or unjust enrichment.   On July 19, 2019, the Company and Typenex executed a settlement agreement. Pursuant to the settlement agreement, the Company agreed to pay Typenex $50,000 in cash and to issue 40,000 shares of the Company’s common stock. As of June 30, 2019, $66,800 is included in accrued expenses within the condensed consolidated balance sheets for this settlement.   NovoTek Therapeutics Inc. and NovoTek Pharmaceuticals Limited v. Akers Biosciences, Inc.   On June 21, 2019, the Company received a complaint, filed by Novotek Therapeutics Inc., and Novotek Pharmaceuticals Limited (collectively, “Novotek”), Beijing-based entities, in the United States District Court for the District of New Jersey, alleging, among other things, breach of contract. Novotek is seeking, among other things, damages in the amount of $1,551,562, plus interest, disbursements and attorneys’ fees. The Company vigorously disputes the allegations in the complaint and has retained counsel to defend it. The Company is not yet able to determine the amount of the Company’s exposure, if any.   Neelima Varma v. Akers Biosciences, Inc. and St. David’s Healthcare Partnership, L.P., LLP CAUSE NO: D-1-GN-19-004262   On July 25, 2019, the Company was notified that on July 23, 2019, a complaint was filed by Neelima Varma, against the Company and St. David’s Healthcare Partnership, L.P., LLP (“St. David’s”), in the district court of Travis County, Texas, alleging, among other things, negligence, gross negligence and strict product liability, breach of express warranty, breach of implied warranty and fraudulent misrepresentation and omission, with respect to a medical device which the Company had sold through one its distributors to St. David’s. Ms. Varma is seeking aggregate monetary relief from the Company and St. David’s in excess of $1,000,000. The Company carries product liability insurance. The insurance carrier has provided notice that it has reserved certain rights. The Company and its insurance carrier will contest this complaint vigorously. The Company believes that its product liability insurance coverage will be adequate to cover the potential exposure for this matter.   Douglas Carrara v. Akers Biosciences, Inc., John Does 1-10, and XYZ Corp. 1-10, Docket No. ESX-L-5272-19 (N.J. Super. Ct., Essex County):   Douglas Carrara, a former executive, has sued the Company over the termination of his employment. The executive seeks contractual severance pay in the amount of $200,000. The executive asserts that the termination was without cause within the meaning of his employment agreement, which provides for severance of one year’s salary in the event of termination without cause. The executive also seeks indemnification for approximately $8,000 in attorneys’ fees that he contends he incurred in regard to company business. With regard to both claims, the executive seeks to recover his attorneys’ fees under a fee-shifting provision in his employment agreement.   The Company’s answer to the complaint is due August 28, 2019. With respect to this matter, the Company believes that the ultimate liability from the resolution of this matter will not be material to the Company’s condensed consolidated financial statements.   Other   A former executive has threatened to sue the Company over the termination of the executive’s employment. The executive contends that the termination was in retaliation for complaints to the employer protected under the California whistleblower protection laws. The executive also contends that the Company failed to pay a bonus in violation of an employment contract. The Company’s management and legal counsel believes it is too early to determine the probable outcome of this matter.   The Company intends to establish a rigorous defense of all claims. All legal fees were expensed as and when incurred.

Trade and other payables consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Trade Payables</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">741,875</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">686,578</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">816,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,227,172</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Deferred Compensation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">59,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,617,718</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,973,500</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The table below summarizes the warrant activity for the period ended June 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Remaining Contractual Term (years)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; font-style: italic">Balance at December 31, 2018</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2,110,737</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">4.21</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">                -</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Canceled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,110,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Exercisable as of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,110,737</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">3.71</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

2110737

3.10 3.10 3.10 P4Y2M16D P3Y8M16D P3Y8M16D

22444

132000 40839 25980

P7Y

6156

82320

83144

20420

19825

40955

40298

12990

6495

12990

10210

9913

P60M

P29M

P24M

200000

On November 15, 2018, Typenex Medical LLC ("Typenex"), a telemarketing entity with whom the Company had entered into a marketing and commission agreement dated September 30, 2016 (the "Marketing Contract"), filed an arbitration against the Company before JAMS ADR (the "Arbitration"), and an arbiter was appointed to the Arbitration on December 14, 2018. In the Arbitration, Typenex has stated that it seeks "at least" $220,500 based on the allegation that the Marketing Contract entitles Typenex to a commission on sales of certain of the Company's heparin-related products in the period two years from the Marketing Contract's expiration

1.00

0.50

0.03

0.05

Note 11 – Employee Benefit Plan   The Company maintains a defined contribution benefit plan under section 401(k) of the Internal Revenue Code covering substantially all qualified employees of the Company (the “401(k) Plan”). Under the 401(k) Plan, the Company matches 100% up to a 3% contribution, and 50% over a 3% contribution, up to a maximum of 5%.   During the three months ended June 30, 2019 and 2018, the Company made matching contributions to the 401(k) Plan of $7,425 and $15,314, respectively and $16,888 and $29,116 for the six months ended June 30, 2019 and 2018, respectively.

16888

29116

7425

15314

Note 3 – Recent Developments and Management’s Plans   On December 19, 2018, the Company announced its intent to delist from the AIM Market of the London Stock Exchange. The Company believed that due to the relatively low liquidity in the Company’s common stock, remaining listed on the AIM Market did not merit the ongoing costs and regulatory complexities associated with maintaining the AIM listing. On March 5, 2019, the Company held a special meeting of shareholders who then voted in favor of the Company delisting from the AIM Market. The delisting took effect on March 29, 2019.   On November 7, 2018, the Company announced that its board of directors had initiated a process to evaluate strategic alternatives to maximize shareholder value. This process will consider a range of potential strategic alternatives including, but not limited to, business combinations, while simultaneously supporting the Company’s management and employees in the execution of the Company’s current business activities. On November 19, 2018, the Company further announced that in its evaluation of strategic alternatives it will consider a range of potential strategic alternatives including, but not limited to, business combinations in sectors different than that currently engaged in, including cannabis and hemp related industries.   By way of a letter dated May 10, 2019, the Listing Qualifications Department of NASDAQ advised the Company that it did not comply with NASDAQ Listing Rule 5550(a)(2) for continued listing, because the Company’s common stock did not meet NASDAQ’s minimum $1.00 bid price requirement (the “Price Requirement”). The Company intends to monitor the closing bid price of the common stock and may, if appropriate, consider implementing available options to regain compliance with the Price Requirement under the NASDAQ Listing Rules.   Historically, the Company has relied upon public offerings and private placements of common stock to raise operating capital. As of August 9, 2019, the Company had cash and marketable securities of approximately $3.99 million (excluding restricted cash of $115,094) and working capital of approximately $3.53 million.   The Company anticipates that available cash and marketable securities, as well as expected cash from operations, will be sufficient to meet its obligations as they fall due within one year after these financial statements are issued. 22444 6570 6570 18206 18206

59002

89514

27581

53173

The schedule of lease commitments is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Thorofare</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Pitman</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Equipment</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Next 6 Months</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">66,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">19,824</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,078</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">88,902</td><td style="width: 1%; text-align: left"> </td></tr></table>

500000

220500

50000

1551562

200000

8000

4247 125500 0 125500 <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"><tr style="font: 10pt Times New Roman, Times, Serif"><td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif"></td> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">(o)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Shipping and Handling Fees and Costs </td></tr> </table>   The Company charges actual shipping costs plus a handling fee to customers, which amounted to $9,511 and $18,739 for the three months ended June 30, 2019 and 2018 and $21,997 and $32,380 for the six months ended June 30, 2019 and 2018, respectively. These fees are classified as part of product revenue in the Condensed Consolidated Statement of Operations and Comprehensive Loss. Shipping and other related delivery costs, including those for incoming raw materials are classified as product cost of sales, which amounted to $15,660 and $37,993 for the three months ended June 30, 2019 and 2018, respectively and $27,579 and $64,937 for the six months ended June 30, 2019 and 2018, respectively.

5534692

1755

12482708

12508958

11780762

12497708

10814256

15000

3125

11250

118478

3906

118478

3906

12545 122384 5175

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 73%; text-align: left">2019 (six months)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 23%; text-align: right">20,004</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,008</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,371</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">223,407</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

A summary of activity related to RSUs for the three months ended June 30, 2019 is presented below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic">Balance at December 31, 2018</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; padding-left: 10pt">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">374,481</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.97</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Canceled/Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">374,481</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; font-style: italic; padding-bottom: 2.5pt">Exercisable as of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

20004

40008

43371

2 1 2 2

14975

27350

9542

13675

3674228

20004

85553

10002

42777

23506 0 0.05 0.50

5000000

549609

2250000

0.97

374481

0.97

47402

-12443

18059

4401

47402

-12443

18059

4401

-1664447

-3939887

-776832

-2063052

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.

0.45

2019-12-31

The lease took effect on August 1, 2017 and runs through December 31, 2019.

The lease took effect on June 1, 2017 and ran through May 31, 2019.

3078

66000

88902

19824

1437875 5717325 1437875 5717325 3811509 966506

-1755000

1755000

-1755

1464930

3469 3469

2742

2712

2742

2712

12545 12545

122384

118478

Note 9 – Related Parties   CEO and Interim CFO   Effective on October 5, 2018, the Board appointed Howard R. Yeaton, to serve as the Chief Executive Officer and interim Chief Financial Officer of the Company. Mr. Yeaton is the managing principal of FCS and the Company’s relationship with FCS shall continue, with FCS continuing to provide accounting services to the Company. FCS is considered to be a related party. During the three and six months ended June 30, 2019, the Company incurred costs of $0 and $23,506 with FCS in connection with these services. As of June 30, 2019, the Company owed FCS $52,913 which is included in trade and other payables on the Condensed Consolidated Balance Sheet.

Yes Yes false

-4330

12512708

-4258

543

4400

Note 12 – Subsequent Event   Pursuant to an unsecured promissory note dated July 4, 2019, on July 25, 2019 the Company advanced $100,000 to a company in the hemp related industry with which the Company has been considering for a potential business transaction. The loan bears interest at a rate of 8% per annum, and is payable in full on October 2, 2019.

47402

18059

1354646

2306675

502126

2004580

6350 43894 7679 16377

240863

P6M

4950

2250000

40000

52913

100000

0.08

2019-10-02

1000000 12443 -4401

115094

3530000

1.00

On July 25, 2019, the Company was notified that on July 23, 2019, a complaint was filed by Neelima Varma, against the Company and St. David's Healthcare Partnership, L.P., LLP ("St. David's"), in the district court of Travis County, Texas, alleging, among other things, negligence, gross negligence and strict product liability, breach of express warranty, breach of implied warranty and fraudulent misrepresentation and omission, with respect to a medical device which the Company had sold through one its distributors to St. David's. Ms. Varma is seeking aggregate monetary relief from the Company and St. David's in excess of $1,000,000.

EX-101.SCH 5 aker-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Recent Developments and Management's Plans link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Trade and Other Payables link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Revenue Information link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Trade and Other Payables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Share-based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenue Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Significant Accounting Policies - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Significant Accounting Policies - Schedule of Future Amortization Expense of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Recent Developments and Management's Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Commitments and Contingencies - Schedule of Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Related Parties (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Revenue Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Revenue Information - Schedule of Revenue by Product Lines (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Revenue Information - Schedule of Revenue by Geographic Area Determined Based On Location of Customers (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Employee Benefit Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Subsequent Event (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 aker-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 aker-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 aker-20190630_lab.xml XBRL LABEL FILE Concentration Risk Benchmark [Axis] Trade Receivable [Member] Geographical [Axis] People's Republic of China [Member] United States [Member] Rest of World [Member] Legal Entity [Axis] MicroParticle Catalyzed Biosensor ("MPC") [Member] Particle ImmunoFiltration Assay ("PIFA") [Member] Other [Member] Equity Components [Axis] Common Stock [Member] Deferred Compensation [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income/(Loss) [Member] Fair Value, Hierarchy [Axis] Level 2 [Member] Rapid Enzymatic Assay ("REA") [Member] Preferred Stock [Member] Warrants [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Settlement Agreement [Member] Level 1 [Member] Level 3 [Member] Customer [Axis] Customer One [Member] Customer Two [Member] Sales Revenue, Net [Member] Trade Payables [Member] Three Vendors [Member] Product and Service [Axis] Shipping and Handling [Member] Thorofare Lease [Member] Equipment Operating Lease [Member] Pitman Lease [Member] Marketing Contract [Member] Range [Axis] Minimum [Member] Retirement Plan Name [Axis] 401 K Plan Matches 50% [Member] 401 K Plan Maximum 5% [Member] Antidilutive Securities [Axis] Stock Options [Member] Warrants [Member] Restricted Stock Units (RSUs) [Member] Maximum [Member] Cost of Goods [Member] Supplier One [Member] Supplier Two [Member] One Supplier [Member] Title of Individual [Axis] Mr. Yeaton [Member] Employment Agreement [Member] Related Party [Axis] Financial Consulting Strategies LLC [Member] ChubeWorkx [Member] Deferred Revenue Arrangement Type [Axis] Royalty [Member] Litigation Case [Axis] Watts Action [Member] Plan Name [Axis] 2013 Stock Incentive Plan [Member] Amended Plan [Member] Award Type [Axis] Restricted Stock [Member] 2017 Stock Incentive Plan [Member] 2018 Stock Incentive Plan [Member] Three Directors [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents, Trademarks and Customer Lists [Member] Customer Three [Member] Vendor One [Member] Vendor Two [Member] Vendor Three [Member] Ramsey Lease [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Novotek Therapeutics Inc., and NovoTek Pharmaceuticals Limited [Member] Neelima Varma and St.David's [Member] Debt Instrument [Axis] Unsecured Promissory Note [Member] St.David's [Member] Douglas Carrara [Member] Loss Contingency Nature [Axis] Severence Pay [Member] Attorneys' Fees [Member] Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity's Reporting Status Current Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Marketable Securities Trade Receivables, net Deposits and other receivables Inventories, net Prepaid expenses Total Current Assets Non-Current Assets Prepaid expenses Restricted Cash Property, Plant and Equipment, net Intangible Assets, net Other Assets Total Non-Current Assets Total Assets LIABILITIES Current Liabilities Trade and Other Payables Total Liabilities Commitments and Contingencies SHAREHOLDERS' EQUITY Convertible Preferred Stock, No par value, 50,000,000 shares authorized, 0 and 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018 Common Stock, No par value, 500,000,000 shares authorized, 12,508,958 and 12,482,708 issued and outstanding as of June 30, 2019 and December 31, 2018 Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Total Shareholders' Equity Total Liabilities and Shareholders' Equity Convertible preferred stock, no par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, no par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Product Revenue Product Cost of Sales Gross Income Administrative Expenses Sales and Marketing Expenses Compliance, Research and Development Expenses Litigation Settlement Expenses Amortization of Non-Current Assets Loss from Operations Other (Income)/Expenses Foreign Currency Transaction Loss Loss on Investments Interest and Dividend Income Total Other Income Loss Before Income Taxes Income Tax Benefit Net Loss Other Comprehensive Gain/(Loss) Net Unrealized Gain/(Loss) on Marketable Securities Total Other Comprehensive Gain/(Loss) Comprehensive Loss Basic and Diluted loss per common share Weighted average basic and diluted common shares outstanding Statement [Table] Statement [Line Items] Balance Balance, shares Net loss Exercise of warrants for common stock Exercise of warrants for common stock, shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock, shares Amortization of deferred compensation Issuance of unrestricted stock to a key employee Issuance of unrestricted stock to a key employee, shares Issuance of restricted stock units to directors for services Issuance of restricted stock units to directors for services, shares Issuance of non-qualified stock options to key employees Issuance of restricted stock for services for non-employees Issuance of restricted stock for services for non-employees, shares Net unrealized gain on marketable securities Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net loss to net cash used in operating activities: Accrued income on marketable securities Depreciation and amortization Reserve for obsolete inventory Reserve for doubtful accounts Loss on sales of securities EX-101.PRE 9 aker-20190630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 09, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	Akers Biosciences, Inc.
Entity Central Index Key	0001321834
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,512,708
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 248,439	$ 181,755
Marketable Securities	4,020,498	5,272,998
Trade Receivables, net	266,860	176,326
Deposits and other receivables		9,347
Inventories, net	544,241	585,267
Prepaid expenses	169,591	444,435
Total Current Assets	5,249,629	6,670,128
Non-Current Assets
Prepaid expenses	267,569	298,256
Restricted Cash	115,094	500,000
Property, Plant and Equipment, net	68,481	83,456
Intangible Assets, net	223,407	243,411
Other Assets	7,672	12,002
Total Non-Current Assets	682,223	1,137,125
Total Assets	5,931,852	7,807,253
Current Liabilities
Trade and Other Payables	1,617,718	1,973,500
Total Liabilities	1,617,718	1,973,500
Commitments and Contingencies
SHAREHOLDERS' EQUITY
Convertible Preferred Stock, No par value, 50,000,000 shares authorized, 0 and 0 shares issued and outstanding as of June 30, 2019 and December 31, 2018
Common Stock, No par value, 500,000,000 shares authorized, 12,508,958 and 12,482,708 issued and outstanding as of June 30, 2019 and December 31, 2018	121,699,375	121,554,547
Accumulated Other Comprehensive Income (Loss)	21,489	(25,913)
Accumulated Deficit	(117,406,730)	(115,694,881)
Total Shareholders' Equity	4,314,134	5,833,753
Total Liabilities and Shareholders' Equity	$ 5,931,852	$ 7,807,253

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Convertible preferred stock, no par value
Convertible preferred stock, shares authorized	50,000,000	50,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, no par value
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	12,508,958	12,482,708
Common stock, shares outstanding	12,508,958	12,482,708

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Product Revenue	$ 464,513	$ 526,601	$ 1,076,634	$ 829,076
Product Cost of Sales	(219,864)	(302,826)	(465,801)	(600,326)
Gross Income	244,649	223,775	610,833	228,750
Administrative Expenses	981,309	1,565,602	1,964,265	2,481,134
Sales and Marketing Expenses	14,139	469,469	163,979	969,620
Compliance, Research and Development Expenses	60,909	259,124	149,300	699,094
Litigation Settlement Expenses			75,000
Amortization of Non-Current Assets	10,002	42,777	20,004	85,554
Loss from Operations	(821,710)	(2,113,197)	(1,761,715)	(4,006,652)
Other (Income)/Expenses
Foreign Currency Transaction Loss	219	3,029	4,878	5,905
Loss on Investments	543	4,400	4,258	4,401
Interest and Dividend Income	(27,581)	(53,173)	(59,002)	(89,514)
Total Other Income	(26,819)	(45,744)	(49,866)	(79,208)
Loss Before Income Taxes	(794,891)	(2,067,453)	(1,711,849)	(3,927,444)
Income Tax Benefit
Net Loss	(794,891)	(2,067,453)	(1,711,849)	(3,927,444)
Other Comprehensive Gain/(Loss)
Net Unrealized Gain/(Loss) on Marketable Securities	18,059	4,401	47,402	(12,443)
Total Other Comprehensive Gain/(Loss)	18,059	4,401	47,402	(12,443)
Comprehensive Loss	$ (776,832)	$ (2,063,052)	$ (1,664,447)	$ (3,939,887)
Basic and Diluted loss per common share	$ (0.06)	$ (0.18)	$ (0.14)	$ (0.38)
Weighted average basic and diluted common shares outstanding	12,500,923	11,656,788	12,492,115	10,293,569

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Deferred Compensation [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Total
Balance at Dec. 31, 2017	$ 1,755,000	$ 110,647,169	$ (3,469)	$ (104,845,847)		$ 7,552,853
Balance, shares at Dec. 31, 2017	1,755	5,534,692
Net loss				(1,859,991)		(1,859,991)
Exercise of warrants for common stock		$ 5,717,325				5,717,325
Exercise of warrants for common stock, shares		3,811,509
Conversion of preferred stock to common stock	$ (1,755,000)	$ 1,755,000
Conversion of preferred stock to common stock, shares	(1,755)	1,464,930
Amortization of deferred compensation			3,469			3,469
Issuance of unrestricted stock to a key employee		$ 5,175				5,175
Issuance of unrestricted stock to a key employee, shares		3,125
Issuance of non-qualified stock options to key employees		$ 2,712				2,712
Issuance of restricted stock for services for non-employees		$ 12,545				12,545
Issuance of restricted stock for services for non-employees, shares
Net unrealized gain on marketable securities					(16,843)	(16,843)
Balance at Mar. 31, 2018		$ 118,139,926		(106,705,838)	(16,843)	11,417,245
Balance, shares at Mar. 31, 2018		10,814,256
Balance at Dec. 31, 2017	$ 1,755,000	$ 110,647,169	(3,469)	(104,845,847)		7,552,853
Balance, shares at Dec. 31, 2017	1,755	5,534,692
Net loss						(3,927,444)
Balance at Jun. 30, 2018		$ 119,580,543		(108,773,291)	(12,443)	10,794,809
Balance, shares at Jun. 30, 2018		11,780,762
Balance at Mar. 31, 2018		$ 118,139,926		(106,705,838)	(16,843)	11,417,245
Balance, shares at Mar. 31, 2018		10,814,256
Net loss				(2,067,453)		(2,067,453)
Exercise of warrants for common stock		$ 1,437,875				1,437,875
Exercise of warrants for common stock, shares		966,506
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock, shares
Amortization of deferred compensation
Issuance of unrestricted stock to a key employee
Issuance of unrestricted stock to a key employee, shares
Issuance of non-qualified stock options to key employees		2,742				2,742
Issuance of restricted stock for services for non-employees
Issuance of restricted stock for services for non-employees, shares
Net unrealized gain on marketable securities					4,400	4,400
Balance at Jun. 30, 2018		$ 119,580,543		(108,773,291)	(12,443)	10,794,809
Balance, shares at Jun. 30, 2018		11,780,762
Balance at Dec. 31, 2018		$ 121,554,547		(115,694,881)	(25,913)	5,833,753
Balance, shares at Dec. 31, 2018		12,482,708
Net loss				(916,958)		(916,958)
Issuance of unrestricted stock to a key employee		$ 15,874				15,874
Issuance of unrestricted stock to a key employee, shares		15,000
Issuance of restricted stock units to directors for services		$ 3,906				3,906
Issuance of restricted stock units to directors for services, shares
Net unrealized gain on marketable securities					29,343	29,343
Balance at Mar. 31, 2019		$ 121,574,327		(116,611,839)	3,430	4,965,918
Balance, shares at Mar. 31, 2019		12,497,708
Balance at Dec. 31, 2018		$ 121,554,547		(115,694,881)	(25,913)	5,833,753
Balance, shares at Dec. 31, 2018		12,482,708
Net loss						(1,711,849)
Balance at Jun. 30, 2019		$ 121,699,375		(117,406,730)	21,489	4,314,134
Balance, shares at Jun. 30, 2019		12,508,958
Balance at Mar. 31, 2019		$ 121,574,327		(116,611,839)	3,430	4,965,918
Balance, shares at Mar. 31, 2019		12,497,708
Net loss				(794,891)		(794,891)
Issuance of unrestricted stock to a key employee		$ 6,570				6,570
Issuance of unrestricted stock to a key employee, shares		11,250
Issuance of restricted stock units to directors for services		$ 118,478				118,478
Issuance of restricted stock units to directors for services, shares
Net unrealized gain on marketable securities					18,059	18,059
Balance at Jun. 30, 2019		$ 121,699,375		$ (117,406,730)	$ 21,489	$ 4,314,134
Balance, shares at Jun. 30, 2019		12,508,958

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net loss	$ (1,711,849)	$ (3,927,444)
Adjustments to reconcile net loss to net cash used in operating activities:
Accrued income on marketable securities	3,514	(16,332)
Depreciation and amortization	34,979	112,903
Reserve for obsolete inventory		32,283
Reserve for doubtful accounts	4,247	97,000
Loss on sales of securities	4,258
Amortization of deferred compensation		3,469
Share based compensation to employees - options		5,454
Share based compensation to an employee	22,444
Share based compensation to directors - restricted stock units	122,384	5,175
Share based compensation to non-employees - restricted stock		12,545
Changes in assets and liabilities:
(Increase)/decrease in trade receivables	(94,781)	455,048
(Increase)/decrease in deposits and other receivables	9,347	(43,941)
(Increase)/decrease in inventories	41,026	(99,220)
(Increase)/decrease in prepaid expenses	305,531	(521,676)
Decrease in other assets	4,330
Increase/(decrease) in trade and other payables	(355,782)	66,844
Net cash used in operating activities	(1,610,352)	(3,817,892)
Cash flows from investing activities
Purchases of property, plant and equipment		(37,698)
Purchases of marketable securities	(62,516)	(5,268,754)
Proceeds from sale of marketable securities	1,354,646	2,306,675
Net cash provided by/(used in) investing activities	1,292,130	(2,999,777)
Cash flows from financing activities
Net proceeds from exercise of warrants for common stock		7,155,200
Net cash provided by financing activities		7,155,200
Net increase/(decrease) in cash and restricted cash	(318,222)	337,531
Cash and restricted cash at beginning of period	681,755	438,432
Cash and restricted cash at end of period	363,533	775,963
Cash paid for:
Interest
Income Taxes
Supplemental Schedule of Non-Cash Financing and Investing Activities
Net unrealized gains/(losses) on marketable securities	47,402	(12,443)
Conversion of Series B Preferred Stock to common shares		$ 1,755,000

XML 16 R7.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of Business

Note 1 – Organization and Description of Business

XML 17 R8.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

Note 2 – Significant Accounting Policies

(a)

Basis of Presentation

The Condensed Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP).

(b)

Use of Estimates and Judgments

(c)

Functional and Presentation Currency

(d)

Comprehensive Income (Loss)

(e)

Cash and Cash Equivalents

(f)

Restricted Cash

(g)

Fair Value of Financial Instruments

	Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

	Level 2	Inputs to the valuation methodology include:

	●	quoted prices for similar assets or liabilities in active markets;

	●	quoted prices for identical or similar assets or liabilities in inactive markets;

	●	inputs other than quoted prices that are observable for the asset or liability;

	●	inputs that are derived principally from or corroborated by observable market data by correlation or other means

	If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3

Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Following is a description of the valuation methodologies used for assets measured at fair value as of June 30, 2019 and December 31, 2018.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at June 30, 2019	$	-	$	4,020,498	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

(h)

Trade Receivables and Allowance for Doubtful Accounts

The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature.

(i)

Concentrations

Major Customers

To limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition.

Major Suppliers

(j)

Property, Plant and Equipment

Depreciation expense totaled $9,542 and $13,675 for the three months ended June 30, 2019 and 2018, respectively and $14,975 and $27,350 for the six months ended June 30, 2019 and 2018, respectively.

(k)

Intangible Assets

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2019 (six months)	$	20,004
2020		40,008
2021		40,008
2022		40,008
2023		40,008
Thereafter		43,371
	$	223,407

(l)

Revenue Recognition

Step 1: Identify the contract with the customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when the company satisfies a performance obligation

(m)

Income Taxes

(o)

Shipping and Handling Fees and Costs

(p)

Basic and Diluted Earnings per Share of Common Stock

Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Three and Six Months Ended June 30,
	2019		2018
Stock Options		4,064		25,250
RSUs		374,481		-
Warrants		2,110,737		1,416,229
Total potentially dilutive shares		2,489,282		1,441,479

(q)

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements Adopted

Recently Issued Accounting Pronouncements Not Adopted

XML 18 R9.htm IDEA: XBRL DOCUMENT

Recent Developments and Management's Plans

6 Months Ended

Jun. 30, 2019

Recent Developments and Management's Plans

Note 3 – Recent Developments and Management’s Plans

XML 19 R10.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2019

Inventory Disclosure [Abstract]

Inventories

Note 4 – Inventories

Inventories consist of the following:

	June 30, 2019			December 31, 2018

Raw Materials	$	404,094		$	542,761
Sub-Assemblies		686,386			711,181
Finished Goods		479,457			635,565
Reserve for Obsolescence		(1,025,696	)		(1,304,240	)
	$	544,241		$	585,267

XML 20 R11.htm IDEA: XBRL DOCUMENT

Trade and Other Payables

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Trade and Other Payables

Note 5 - Trade and Other Payables

Trade and other payables consists of the following:

	June 30, 2019		December 31, 2018

Trade Payables	$	741,875	$	686,578
Accrued Expenses		816,093		1,227,172
Deferred Compensation		59,750		59,750
	$	1,617,718	$	1,973,500

See also Note 9 for related party information.

XML 21 R12.htm IDEA: XBRL DOCUMENT

Share-based Payments

6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Share-based Payments

Note 6 - Share-based Payments

Equity incentive Plans

2013 Stock Incentive Plan

2017 Stock Incentive Plan

2018 Stock Incentive Plan

Stock Options

The following table summarizes the option activities for the six months ended June 30, 2019:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		10,502		$	30.41	$	17.42		1.43	$	-
Granted		-			-		-		-		-
Exercised		-			-		-		-		-
Forfeited		(6,438	)		33.79		23.72		0.58		-
Canceled/Expired		-			-		-		-		-
Balance at June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-
Exercisable as of June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-

As of June 30, 2019, all of the Company’s outstanding stock options were fully vested and exercisable.

Restricted Stock Units

	Number of RSUs		Weighted Average Grant Date Fair Value
Balance at December 31, 2018		-	$	-
Granted		374,481	$	0.97
Exercised		-		-
Forfeited		-		-
Canceled/Expired		-		-
Balance at June 30, 2019		374,481	$	0.97
Exercisable as of June 30, 2019		-		-

During the three and six months ended June 30, 2019, the Company incurred RSU expense of $118,478 and $122,384, respectively.

Stock Warrants

The table below summarizes the warrant activity for the period ended June 30, 2019:

	Number of Warrants		Weighted Average Exercise Price		Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		2,110,737	$	3.10		4.21	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Canceled/Expired		-		-		-		-
Balance at June 30, 2019		2,110,737	$	3.10		3.71	$	-
Exercisable as of June 30, 2019		2,110,737	$	3.10		3.71	$	-

XML 22 R13.htm IDEA: XBRL DOCUMENT

Equity

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Equity

Note 7 – Equity

XML 23 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 8 – Commitments and Contingencies

Lease Commitments

The Company entered into a 60-month operating lease for equipment with annual rentals of $6,156 on September 29, 2014. The lease commenced on October 21, 2014 upon the delivery of the equipment.

The schedule of lease commitments is as follows:

	Thorofare		Pitman		Equipment
	Lease		Lease		Lease		Total
Next 6 Months	$	66,000	$	19,824	$	3,078	$	88,902

ChubeWorkx

Litigation and Settlements

Faulkner v. Akers Biosciences, Inc., No. 2:18-cv-10521 (D.N.J.) and Gleason v. Akers Biosciences, Inc., No. 2:18-cv-10805 (D.N.J.)

Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.)

Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.)

Watts and Chan Matters – Potential Resolution

Faulkner, Gleason, Watts and Chan Matters

Typenex Medical, LLC v. Akers Biosciences, Inc., JAMS Ref. No. 1450005929

NovoTek Therapeutics Inc. and NovoTek Pharmaceuticals Limited v. Akers Biosciences, Inc.

Neelima Varma v. Akers Biosciences, Inc. and St. David’s Healthcare Partnership, L.P., LLP CAUSE NO: D-1-GN-19-004262

Douglas Carrara v. Akers Biosciences, Inc., John Does 1-10, and XYZ Corp. 1-10, Docket No. ESX-L-5272-19 (N.J. Super. Ct., Essex County):

Other

The Company intends to establish a rigorous defense of all claims. All legal fees were expensed as and when incurred.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Related Parties

6 Months Ended

Jun. 30, 2019

Related Parties

Note 9 – Related Parties

CEO and Interim CFO

XML 25 R16.htm IDEA: XBRL DOCUMENT

Revenue Information

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Revenue Information

Note 10 – Revenue Information

Revenue by product lines was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Product Line	2019		2018		2019		2018
MicroParticle Catalyzed Biosensor (“MPC”)	$	65,344	$	106,680	$	88,664	$	125,630
Particle ImmunoFiltration Assay (“PIFA”)		304,658		356,082		880,973		616,066
Rapid Enzymatic Assay (“REA”)		85,000		45,100		85,000		55,000
Other		9,511		18,739		21,997		32,380
Total Revenue	$	464,513	$	526,601	$	1,076,634	$	829,076

The total revenue by geographic area determined based on the location of the customers was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Geographic Region	2019		2018		2019		2018
United States	$	447,013	$	462,383	$	1,059,134	$	757,116
Rest of World		17,500		64,218		17,500		71,960
Total Revenue	$	464,513	$	526,601	$	1,076,634	$	829,076

XML 26 R17.htm IDEA: XBRL DOCUMENT

Employee Benefit Plan

6 Months Ended

Jun. 30, 2019

Retirement Benefits [Abstract]

Employee Benefit Plan

Note 11 – Employee Benefit Plan

XML 27 R18.htm IDEA: XBRL DOCUMENT

Subsequent Event

6 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

Subsequent Event

Note 12 – Subsequent Event

XML 28 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

(a)

Basis of Presentation

The Condensed Consolidated Financial Statements of the Company are prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the United States of America (US GAAP).

Use of Estimates and Judgments

(b)

Use of Estimates and Judgments

Functional and Presentation Currency

(c)

Functional and Presentation Currency

Comprehensive Income (loss)

(d)

Comprehensive Income (Loss)

Cash and Cash Equivalents

(e)

Cash and Cash Equivalents

Restricted Cash

(f)

Restricted Cash

Fair Value of Financial Instruments

(g)

Fair Value of Financial Instruments

	Level 1	Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

	Level 2	Inputs to the valuation methodology include:

	●	quoted prices for similar assets or liabilities in active markets;

	●	quoted prices for identical or similar assets or liabilities in inactive markets;

	●	inputs other than quoted prices that are observable for the asset or liability;

	●	inputs that are derived principally from or corroborated by observable market data by correlation or other means

	If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3

Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Following is a description of the valuation methodologies used for assets measured at fair value as of June 30, 2019 and December 31, 2018.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at June 30, 2019	$	-	$	4,020,498	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

Trade Receivables and Allowance for Doubtful Accounts

(h)

Trade Receivables and Allowance for Doubtful Accounts

The carrying amounts of current trade receivables is stated at cost, net of allowance for doubtful accounts and approximate their fair value given their short-term nature.

Concentrations

(i)

Concentrations

Major Customers

To limit such risks, the Company performs ongoing credit evaluations of its customers’ financial condition.

Major Suppliers

Property, Plant and Equipment

(j)

Property, Plant and Equipment

Depreciation expense totaled $9,542 and $13,675 for the three months ended June 30, 2019 and 2018, respectively and $14,975 and $27,350 for the six months ended June 30, 2019 and 2018, respectively.

Intangible Assets

(k)

Intangible Assets

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2019 (six months)	$	20,004
2020		40,008
2021		40,008
2022		40,008
2023		40,008
Thereafter		43,371
	$	223,407

Revenue Recognition

(l)

Revenue Recognition

Step 1: Identify the contract with the customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when the company satisfies a performance obligation

Income Taxes

(m)

Income Taxes

Shipping and Handling Fees and Costs

(o)

Shipping and Handling Fees and Costs

Basic and Diluted Earnings Per Share of Common Stock

(p)

Basic and Diluted Earnings per Share of Common Stock

Diluted net loss per share is computed using the weighted average number of common and dilutive potential common shares outstanding during the period.

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Three and Six Months Ended June 30,
	2019		2018
Stock Options		4,064		25,250
RSUs		374,481		-
Warrants		2,110,737		1,416,229
Total potentially dilutive shares		2,489,282		1,441,479

Recently Issued Accounting Pronouncements

(q)

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements Adopted

Recently Issued Accounting Pronouncements Not Adopted

XML 29 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Marketable Securities

This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)		Quoted Prices for Similar Assets or Liabilities in Active Markets (Level 2)		Significant Unobservable Inputs (Level 3)
Marketable securities at June 30, 2019	$	-	$	4,020,498	$	-

Marketable securities at December 31, 2018	$	-	$	5,272,998	$	-

Schedule of Future Amortization Expense of Intangible Assets

The following is an annual schedule of approximate future amortization of the Company’s intangible assets:

Period	Amount
2019 (six months)	$	20,004
2020		40,008
2021		40,008
2022		40,008
2023		40,008
Thereafter		43,371
	$	223,407

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:

	For the Three and Six Months Ended June 30,
	2019		2018
Stock Options		4,064		25,250
RSUs		374,481		-
Warrants		2,110,737		1,416,229
Total potentially dilutive shares		2,489,282		1,441,479

XML 30 R21.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Jun. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	June 30, 2019			December 31, 2018

Raw Materials	$	404,094		$	542,761
Sub-Assemblies		686,386			711,181
Finished Goods		479,457			635,565
Reserve for Obsolescence		(1,025,696	)		(1,304,240	)
	$	544,241		$	585,267

XML 31 R22.htm IDEA: XBRL DOCUMENT

Trade and Other Payables (Tables)

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Schedule of Trade and Other Payables

Trade and other payables consists of the following:

	June 30, 2019		December 31, 2018

Trade Payables	$	741,875	$	686,578
Accrued Expenses		816,093		1,227,172
Deferred Compensation		59,750		59,750
	$	1,617,718	$	1,973,500

XML 32 R23.htm IDEA: XBRL DOCUMENT

Share-based Payments (Tables)

6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Summary of Stock Options Activity

The following table summarizes the option activities for the six months ended June 30, 2019:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Grant Date Fair Value		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		10,502		$	30.41	$	17.42		1.43	$	-
Granted		-			-		-		-		-
Exercised		-			-		-		-		-
Forfeited		(6,438	)		33.79		23.72		0.58		-
Canceled/Expired		-			-		-		-		-
Balance at June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-
Exercisable as of June 30, 2019		4,064		$	25.04	$	7.46		1.50	$	-

Summary of Restricted Stock Units Activity

A summary of activity related to RSUs for the three months ended June 30, 2019 is presented below:

	Number of RSUs		Weighted Average Grant Date Fair Value
Balance at December 31, 2018		-	$	-
Granted		374,481	$	0.97
Exercised		-		-
Forfeited		-		-
Canceled/Expired		-		-
Balance at June 30, 2019		374,481	$	0.97
Exercisable as of June 30, 2019		-		-

Summary of Warrant Activity

The table below summarizes the warrant activity for the period ended June 30, 2019:

	Number of Warrants		Weighted Average Exercise Price		Average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Balance at December 31, 2018		2,110,737	$	3.10		4.21	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Canceled/Expired		-		-		-		-
Balance at June 30, 2019		2,110,737	$	3.10		3.71	$	-
Exercisable as of June 30, 2019		2,110,737	$	3.10		3.71	$	-

XML 33 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Schedule of Lease Commitments

The schedule of lease commitments is as follows:

	Thorofare		Pitman		Equipment
	Lease		Lease		Lease		Total
Next 6 Months	$	66,000	$	19,824	$	3,078	$	88,902

XML 34 R25.htm IDEA: XBRL DOCUMENT

Revenue Information (Tables)

6 Months Ended

Jun. 30, 2019

Segment Reporting [Abstract]

Schedule of Revenue by Product Lines

Revenue by product lines was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Product Line	2019		2018		2019		2018
MicroParticle Catalyzed Biosensor (“MPC”)	$	65,344	$	106,680	$	88,664	$	125,630
Particle ImmunoFiltration Assay (“PIFA”)		304,658		356,082		880,973		616,066
Rapid Enzymatic Assay (“REA”)		85,000		45,100		85,000		55,000
Other		9,511		18,739		21,997		32,380
Total Revenue	$	464,513	$	526,601	$	1,076,634	$	829,076

Schedule of Revenue by Geographic Area Determined Based On Location of Customers

The total revenue by geographic area determined based on the location of the customers was as follows:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Geographic Region	2019		2018		2019		2018
United States	$	447,013	$	462,383	$	1,059,134	$	757,116
Rest of World		17,500		64,218		17,500		71,960
Total Revenue	$	464,513	$	526,601	$	1,076,634	$	829,076

XML 35 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative)	3 Months Ended		6 Months Ended		12 Months Ended
Significant Accounting Policies (Details Narrative)	Jun. 30, 2019 USD ($) Breathalyzers shares	Jun. 30, 2018 USD ($) Breathalyzers shares	Jun. 30, 2019 USD ($) Breathalyzers shares	Jun. 30, 2018 USD ($) Breathalyzers shares	Dec. 31, 2018 USD ($) Breathalyzers
Restricted cash	$ 115,094		$ 115,094		$ 500,000
Maturities of securities			less than one year
Unrealized gain on securities	18,059		$ 47,402
Unrealized loss on securities		$ (4,401)		$ 12,443
Marketable securities, loss	543	4,400	(4,258)
Proceeds from sale of marketable securities	502,126	2,004,580	1,354,646	2,306,675
Allowances for doubtful accounts for trade receivables	605,848		605,848		606,835
Bad debt expenses	0	125,500	4,247	125,500
Trade receivables	266,860		266,860		176,326
Depreciation expense	9,542	13,675	14,975	27,350
Intangible assets, net	223,407		223,407		243,411
Amortization expense	10,002	42,777	20,004	85,553
Accrued liabilities	1,000		1,000		23,179
Rebates recognized during period	7,679	16,377	$ 6,350	43,894
Income tax examination, likelihood percentage			The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon settlement.
Unrecognized tax benefits
Income tax benefit
Accrued for penalties and interest
Product cost of sales	219,864	302,826	465,801	600,326
Cost of net revenue	15,660	37,993	27,579	64,937
Net loss attributable to common shareholders	$ 794,891	$ 2,067,453	$ 1,711,849	$ 3,927,444
Weighted average basic and diluted common shares outstanding \| shares	12,500,923	11,656,788	12,492,115	10,293,569
Shipping and Handling [Member]
Product cost of sales	$ 9,511	$ 18,739	$ 21,997	$ 13,641
Patents, Trademarks and Customer Lists [Member]
Intangible assets, net	3,897,635		3,897,635
Intangible assets, accumulated amortization	$ 3,674,228		$ 3,674,228
Sales Revenue, Net [Member]
Concentration risk percentage	81.00%	72.00%	78.00%	66.00%
Concentration risk, number of customer \| Breathalyzers	3		3	2
Sales Revenue, Net [Member] \| Customer One [Member]
Concentration risk percentage	42.00%	33.00%	45.00%	49.00%
Sales Revenue, Net [Member] \| Customer Two [Member]
Concentration risk percentage	20.00%	27.00%	44.00%	17.00%
Sales Revenue, Net [Member] \| Customer Three [Member]
Concentration risk percentage	19.00%	12.00%
Trade Receivable [Member]
Concentration risk percentage			76.00%		73.00%
Concentration risk, number of customer \| Breathalyzers			2		2
Trade Receivable [Member] \| Customer One [Member]
Concentration risk percentage			53.00%		59.00%
Trade receivables	$ 458,902		$ 458,902		$ 458,902
Trade Receivable [Member] \| Customer Two [Member]
Concentration risk percentage			23.00%		14.00%
Trade receivables	$ 201,330		$ 201,330		$ 111,037
Cost of Goods [Member]
Concentration risk percentage	76.00%	24.00%	50.00%
Concentration risk, number of supplier \| Breathalyzers	2	2	1
Cost of Goods [Member] \| Supplier Two [Member]
Concentration risk percentage	66.00%	11.00%
Cost of Goods [Member] \| Supplier One [Member]
Concentration risk percentage	0.00%	13.00%
Trade Payables [Member] \| Three Vendors [Member]
Concentration risk percentage			70.00%
Concentration risk, number of supplier \| Breathalyzers			2
Trade Payables [Member] \| Vendor One [Member]
Trade receivables	$ 180,114		$ 180,114
Trade Payables [Member] \| Vendor Two [Member]
Trade receivables	123,000		123,000
Trade Payables [Member] \| Vendor Three [Member]
Trade receivables	$ 116,206		$ 116,206
Minimum [Member]
Normal credit terms extended to customers			30 days
Minimum [Member] \| Cost of Goods [Member] \| One Supplier [Member]
Concentration risk percentage
Concentration risk, number of supplier \| Breathalyzers
Maximum [Member]
Normal credit terms extended to customers			90 days

XML 36 R27.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Marketable Securities (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Level 1 [Member]
Marketable securities
Level 2 [Member]
Marketable securities	4,020,498	5,272,998
Level 3 [Member]
Marketable securities

XML 37 R28.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Future Amortization Expense of Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
2019 (nine months)	$ 20,004
2020	40,008
2021	40,008
2022	40,008
2023	40,008
Thereafter	43,371
Intangible assets, net	$ 223,407	$ 243,411

XML 38 R29.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Total potentially dilutive shares	2,489,282	1,441,479
Stock Options [Member]
Total potentially dilutive shares	4,064	25,250
Restricted Stock Units (RSUs) [Member]
Total potentially dilutive shares	374,481
Warrants [Member]
Total potentially dilutive shares	2,110,737	1,416,229

XML 39 R30.htm IDEA: XBRL DOCUMENT

Recent Developments and Management's Plans (Details Narrative) - USD ($)	Aug. 09, 2019	May 10, 2019
Nasdaq minimum bid price requirement		$ 1.00
Subsequent Event [Member]
Cash and marketable securities	$ 3,990,000
Restricted cash	115,094
Working capital	$ 3,530,000

XML 40 R31.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Inventories (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Inventory Disclosure [Abstract]
Cost of goods sold for obsolete inventory	$ 41,849	$ 7,477		$ 32,283

XML 41 R32.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials	$ 404,094	$ 542,761
Sub-Assemblies	686,386	711,181
Finished Goods	479,457	635,565
Reserve for Obsolescence	(1,025,696)	(1,304,240)
Total Inventory, Net	$ 544,241	$ 585,267

XML 42 R33.htm IDEA: XBRL DOCUMENT

Trade and Other Payables - Schedule of Trade and Other Payables (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Trade Payables	$ 741,875	$ 686,578
Accrued Expenses	816,093	1,227,172
Deferred Compensation	59,750	59,750
Trade and Other Payables, Total	$ 1,617,718	$ 1,973,500

XML 43 R34.htm IDEA: XBRL DOCUMENT

Share-based Payments (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Share-based Payments (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 29, 2019	Dec. 31, 2018	Dec. 07, 2018	Aug. 07, 2017	Jan. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price of common stock	$ 0.45		$ 0.45
Aggregate intrinsic value
Stock options expenses	$ 0	$ 2,742		$ 5,454
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing stock price of common stock	$ 0.45		$ 0.45
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value	$ 0.97		$ 0.97
Restricted stock unit expense	$ 118,478		$ 122,384
Restricted Stock Units (RSUs) [Member] \| Three Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized during period					124,827
Grant date fair value					$ 0.97
Unamortized value	$ 240,863		$ 240,863
Weighted average period			6 months
2013 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized during period									103,750
Amended Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of available for grants	32,160		32,160
Amended Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option to purchase shares of common stock			71,590
2017 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized during period								168,750
Number of available for grants	106,468		106,468
2017 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option to purchase shares of common stock			62,282
2018 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized during period							1,875,000
Number of available for grants	1,500,519		1,500,519
2018 Stock Incentive Plan [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option to purchase shares of common stock			374,481

XML 44 R35.htm IDEA: XBRL DOCUMENT

Share-based Payments - Summary of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2019 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Number of Shares, Beginning Balance \| shares	10,502
Number of Shares, Granted \| shares
Number of Shares, Exercised \| shares
Number of Shares, Forfeited \| shares	(6,438)
Number of Shares, Cancelled/Expired \| shares
Number of Shares, Ending Balance \| shares	4,064
Number of Shares, Exercisable \| shares	4,064
Weighted Average Exercise Price, Beginning Balance	$ 30.41
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited	33.79
Weighted Average Exercise Price, Cancelled/Expired
Weighted Average Exercise Price, Ending Balance	25.04
Weighted Average Exercise Price, Exercisable	25.04
Weighted Average Grant Date Fair Value, Beginning	17.42
Weighted Average Grant Date Fair Value, Granted
Weighted Average Grant Date Fair Value, Exercised
Weighted Average Grant Date Fair Value, Forfeited	23.72
Weighted Average Grant Date Fair Value, Cancelled/Expired
Weighted Average Grant Date Fair Value, Ending	7.46
Weighted Average Grant Date Fair Value, Exercisable	$ 7.46
Weighted Average Remaining Contractual Term (Years), Beginning	1 year 5 months 5 days
Weighted Average Remaining Contractual Term (Years), Granted	0 years
Weighted Average Remaining Contractual Term (Years), Exercised	0 years
Weighted Average Remaining Contractual Term (Years), Forfeited	6 months 29 days
Weighted Average Remaining Contractual Term (Years), Cancelled/Expired	0 years
Weighted Average Remaining Contractual Term (Years), Ending	1 year 6 months
Weighted Average Remaining Contractual Term (Years), Exercisable	1 year 6 months
Aggregate Intrinsic Value, Beginning Balance \| $
Aggregate Intrinsic Value, Ending Balance \| $
Aggregate Intrinsic Value, Exercisable \| $

XML 45 R36.htm IDEA: XBRL DOCUMENT

Share-based Payments - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Number of RSUs, Beginning Balance \| shares
Number of RSUs, Granted \| shares	374,481
Number of RSUs, Exercised \| shares
Number of RSUs, Forfeited \| shares
Number of RSUs, Cancelled/Expired \| shares
Number of RSUs, Ending Balance \| shares	374,481
Number of RSUs, Exercisable \| shares
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares
Weighted Average Grant Date Fair Value, Granted \| $ / shares	0.97
Weighted Average Grant Date Fair Value, Exercised \| $ / shares
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares
Weighted Average Grant Date Fair Value, Cancelled/Expired \| $ / shares
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	0.97
Weighted Average Grant Date Fair Value, Exercisable \| $ / shares

XML 46 R37.htm IDEA: XBRL DOCUMENT

Share-based Payments - Summary of Warrant Activity (Details) - Warrants [Member]	6 Months Ended
	Jun. 30, 2019 USD ($) $ / shares shares
Number of Warrants, Beginning Balance \| shares	2,110,737
Number of Warrants, Granted \| shares
Number of Warrants, Exercised \| shares
Number of Warrants, Forfeited \| shares
Number of Warrants, Cancelled/Expired \| shares
Number of Warrants, Ending Balance \| shares	2,110,737
Number of Warrants, Exercisable \| shares	2,110,737
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 3.10
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Forfeited \| $ / shares
Weighted Average Exercise Price, Cancelled/Expired \| $ / shares
Weighted Average Exercise Price, Ending Balance \| $ / shares	3.10
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 3.10
Weighted Average Remaining Contractual Term (years), Beginning	4 years 2 months 16 days
Weighted Average Remaining Contractual Term (years), Ending	3 years 8 months 16 days
Weighted Average Remaining Contractual Term (years), Exercisable	3 years 8 months 16 days
Aggregate Intrinsic Value, Beginning \| $
Aggregate Intrinsic Value, Ending \| $
Aggregate Intrinsic Value, Exercisable \| $

XML 47 R38.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Equity (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Trade and other payables	$ 1,617,718		$ 1,617,718		$ 1,973,500
Share based compensation expense			22,444
Mr. Yeaton [Member] \| Employment Agreement [Member]
Number of common stock issued			26,250
Fair value of shares based on share price on date of grant			22,444
Trade and other payables					$ 4,238
Share based compensation expense	$ 6,570	$ 18,206	$ 6,570	$ 18,206

XML 48 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)										3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 24, 2019	Jul. 19, 2019	Mar. 08, 2019	Jan. 25, 2019	Jan. 21, 2019	Jan. 14, 2019	Nov. 15, 2018	Sep. 29, 2014	Jan. 07, 2013	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Sep. 24, 2014
Royalty expenses										$ 23,250	$ 27,082	$ 54,804	$ 58,771
Accrued expenses										1,000		1,000		$ 23,179
Douglas Carrara [Member] \| Severence Pay [Member]
Loss Contingency, Damages Sought, Value												200,000
Douglas Carrara [Member] \| Attorneys' Fees [Member]
Loss Contingency, Damages Sought, Value												8,000
Novotek Therapeutics Inc., and NovoTek Pharmaceuticals Limited [Member]
Loss Contingency, Damages Sought, Value					$ 1,551,562
Neelima Varma and St.David's [Member]
Loss contingency, seeking description				On July 25, 2019, the Company was notified that on July 23, 2019, a complaint was filed by Neelima Varma, against the Company and St. David's Healthcare Partnership, L.P., LLP ("St. David's"), in the district court of Travis County, Texas, alleging, among other things, negligence, gross negligence and strict product liability, breach of express warranty, breach of implied warranty and fraudulent misrepresentation and omission, with respect to a medical device which the Company had sold through one its distributors to St. David's. Ms. Varma is seeking aggregate monetary relief from the Company and St. David's in excess of $1,000,000.
St.David's [Member]
Loss contingency, seeking excess value				$ 1,000,000
ChubeWorkx [Member]
Royalty expenses												11,760
Thorofare Lease [Member]
Operating lease with annual rentals including common area maintenance												132,000
Lease agreement, extended term									7 years
Lease agreement, expiration date									Dec. 31, 2019
Rent expense										40,955	40,298	82,320	83,144
Ramsey Lease [Member]
Operating lease with annual rentals including common area maintenance												25,980
Rent expense										$ 6,495	6,495	$ 12,990	12,990
Lease, term of agreement										24 months		24 months
Lease agreement, term description												The lease took effect on June 1, 2017 and ran through May 31, 2019.
Pitman Lease [Member]
Operating lease with annual rentals including common area maintenance												$ 40,839
Rent expense								$ 6,156		$ 10,210	$ 9,913	$ 20,420	$ 19,825
Lease, term of agreement										29 months		29 months			60 months
Lease agreement, term description												The lease took effect on August 1, 2017 and runs through December 31, 2019.
Security deposit										$ 4,950		$ 4,950
Settlement Agreement [Member]
Settlement agreed amount			$ 2,250,000
Insurance coverage amount														500,000
Loss Contingency, Damages Sought, Value														$ 500,000
Settlement Agreement [Member] \| Watts Action [Member]
Payment of attorney' fees						$ 200,000
Settlement Agreement [Member] \| Subsequent Event [Member]
Settlement payment	$ 2,250,000
Loss Contingency, Damages Sought, Value		$ 50,000
Stock to be issued for settlement during the period		40,000
Accrued expenses		$ 66,800
Settlement Agreement [Member] \| ChubeWorkx [Member]
Percentage of royalty received												5.00%
Percentage of royalty retain												50.00%
Due to related parties owned										$ 549,609		$ 549,609
Settlement Agreement [Member] \| ChubeWorkx [Member] \| Royalty [Member]
Royalty revenue												$ 5,000,000
Marketing Contract [Member]
Allegations, description							On November 15, 2018, Typenex Medical LLC ("Typenex"), a telemarketing entity with whom the Company had entered into a marketing and commission agreement dated September 30, 2016 (the "Marketing Contract"), filed an arbitration against the Company before JAMS ADR (the "Arbitration"), and an arbiter was appointed to the Arbitration on December 14, 2018. In the Arbitration, Typenex has stated that it seeks "at least" $220,500 based on the allegation that the Marketing Contract entitles Typenex to a commission on sales of certain of the Company's heparin-related products in the period two years from the Marketing Contract's expiration
Marketing Contract [Member] \| Minimum [Member]
Loss Contingency, Damages Sought, Value							$ 220,500

XML 49 R40.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Lease Commitments (Details)	Jun. 30, 2019 USD ($)
Lease commitments, Next 6 Months	$ 88,902
Thorofare Lease [Member]
Lease commitments, Next 6 Months	66,000
Pitman Lease [Member]
Lease commitments, Next 6 Months	19,824
Equipment Operating Lease [Member]
Lease commitments, Next 6 Months	$ 3,078

XML 50 R41.htm IDEA: XBRL DOCUMENT

Related Parties (Details Narrative) - Financial Consulting Strategies LLC [Member]	3 Months Ended	6 Months Ended
	Jun. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)
Paid to related party	$ 0	$ 23,506
Trade and other payables - related Party	$ 52,913	$ 52,913

XML 51 R42.htm IDEA: XBRL DOCUMENT

Revenue Information (Details Narrative) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
People's Republic of China [Member]
Long-lived assets	$ 13,097	$ 14,294
United States [Member]
Long-lived assets	$ 278,791	$ 312,573

XML 52 R43.htm IDEA: XBRL DOCUMENT

Revenue Information - Schedule of Revenue by Product Lines (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total product Revenues	$ 464,513	$ 526,601	$ 1,076,634	$ 829,076
MicroParticle Catalyzed Biosensor ("MPC") [Member]
Total product Revenues	65,344	106,680	88,664	125,630
Particle ImmunoFiltration Assay ("PIFA") [Member]
Total product Revenues	304,658	356,082	880,973	616,066
Rapid Enzymatic Assay ("REA") [Member]
Total product Revenues	85,000	45,100	85,000	55,000
Other [Member]
Total product Revenues	$ 9,511	$ 18,739	$ 21,997	$ 32,380

XML 53 R44.htm IDEA: XBRL DOCUMENT

Revenue Information - Schedule of Revenue by Geographic Area Determined Based On Location of Customers (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total Revenues	$ 464,513	$ 526,601	$ 1,076,634	$ 829,076
United States [Member]
Total Revenues	447,013	462,383	1,059,134	757,116
Rest of World [Member]
Total Revenues	$ 17,500	$ 64,218	$ 17,500	$ 71,960

XML 54 R45.htm IDEA: XBRL DOCUMENT

Employee Benefit Plan (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
Employee Benefit Plan (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Percentage of matching contribution			100.00%
Percentage of employers contribution based upon employee's pay			3.00%
Employer contribution amount	$ 7,425	$ 15,314	$ 16,888	$ 29,116
401 K Plan Matches 50% [Member]
Percentage of matching contribution			50.00%
Percentage of employers contribution based upon employee's pay			3.00%
401 K Plan Maximum 5% [Member]
Percentage of matching contribution
Percentage of employers contribution based upon employee's pay			5.00%

XML 55 R46.htm IDEA: XBRL DOCUMENT

Subsequent Event (Details Narrative) - Subsequent Event [Member] - Unsecured Promissory Note [Member]	Jul. 25, 2019 USD ($)
Advances to related party	$ 100,000
Interest rate	8.00%
Maturity date	Oct. 02, 2019

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 57 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 217 365 1 false 66 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://akersbio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://akersbio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://akersbio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://akersbio.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Sheet http://akersbio.com/role/StatementsOfChangesInShareholdersEquity Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://akersbio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Organization and Description of Business Sheet http://akersbio.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 7 false false R8.htm 00000008 - Disclosure - Significant Accounting Policies Sheet http://akersbio.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Recent Developments and Management's Plans Sheet http://akersbio.com/role/RecentDevelopmentsAndManagementsPlans Recent Developments and Management's Plans Notes 9 false false R10.htm 00000010 - Disclosure - Inventories Sheet http://akersbio.com/role/Inventories Inventories Notes 10 false false R11.htm 00000011 - Disclosure - Trade and Other Payables Sheet http://akersbio.com/role/TradeAndOtherPayables Trade and Other Payables Notes 11 false false R12.htm 00000012 - Disclosure - Share-based Payments Sheet http://akersbio.com/role/Share-basedPayments Share-based Payments Notes 12 false false R13.htm 00000013 - Disclosure - Equity Sheet http://akersbio.com/role/Equity Equity Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://akersbio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Related Parties Sheet http://akersbio.com/role/RelatedParties Related Parties Notes 15 false false R16.htm 00000016 - Disclosure - Revenue Information Sheet http://akersbio.com/role/RevenueInformation Revenue Information Notes 16 false false R17.htm 00000017 - Disclosure - Employee Benefit Plan Sheet http://akersbio.com/role/EmployeeBenefitPlan Employee Benefit Plan Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Event Sheet http://akersbio.com/role/SubsequentEvent Subsequent Event Notes 18 false false R19.htm 00000019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://akersbio.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://akersbio.com/role/SignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Significant Accounting Policies (Tables) Sheet http://akersbio.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://akersbio.com/role/SignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Inventories (Tables) Sheet http://akersbio.com/role/InventoriesTables Inventories (Tables) Tables http://akersbio.com/role/Inventories 21 false false R22.htm 00000022 - Disclosure - Trade and Other Payables (Tables) Sheet http://akersbio.com/role/TradeAndOtherPayablesTables Trade and Other Payables (Tables) Tables http://akersbio.com/role/TradeAndOtherPayables 22 false false R23.htm 00000023 - Disclosure - Share-based Payments (Tables) Sheet http://akersbio.com/role/SharebasedPaymentsTables Share-based Payments (Tables) Tables http://akersbio.com/role/Share-basedPayments 23 false false R24.htm 00000024 - Disclosure - Commitments and Contingencies (Tables) Sheet http://akersbio.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://akersbio.com/role/CommitmentsAndContingencies 24 false false R25.htm 00000025 - Disclosure - Revenue Information (Tables) Sheet http://akersbio.com/role/RevenueInformationTables Revenue Information (Tables) Tables http://akersbio.com/role/RevenueInformation 25 false false R26.htm 00000026 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://akersbio.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://akersbio.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - Significant Accounting Policies - Schedule of Marketable Securities (Details) Sheet http://akersbio.com/role/SignificantAccountingPolicies-ScheduleOfMarketableSecuritiesDetails Significant Accounting Policies - Schedule of Marketable Securities (Details) Details 27 false false R28.htm 00000028 - Disclosure - Significant Accounting Policies - Schedule of Future Amortization Expense of Intangible Assets (Details) Sheet http://akersbio.com/role/SignificantAccountingPolicies-ScheduleOfFutureAmortizationExpenseOfIntangibleAssetsDetails Significant Accounting Policies - Schedule of Future Amortization Expense of Intangible Assets (Details) Details 28 false false R29.htm 00000029 - Disclosure - Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://akersbio.com/role/SignificantAccountingPolicies-ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 29 false false R30.htm 00000030 - Disclosure - Recent Developments and Management's Plans (Details Narrative) Sheet http://akersbio.com/role/RecentDevelopmentsAndManagementsPlansDetailsNarrative Recent Developments and Management's Plans (Details Narrative) Details http://akersbio.com/role/RecentDevelopmentsAndManagementsPlans 30 false false R31.htm 00000031 - Disclosure - Inventories (Details Narrative) Sheet http://akersbio.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://akersbio.com/role/InventoriesTables 31 false false R32.htm 00000032 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://akersbio.com/role/Inventories-ScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 32 false false R33.htm 00000033 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details) Sheet http://akersbio.com/role/TradeAndOtherPayables-ScheduleOfTradeAndOtherPayablesDetails Trade and Other Payables - Schedule of Trade and Other Payables (Details) Details 33 false false R34.htm 00000034 - Disclosure - Share-based Payments (Details Narrative) Sheet http://akersbio.com/role/Share-basedPaymentsDetailsNarrative Share-based Payments (Details Narrative) Details http://akersbio.com/role/SharebasedPaymentsTables 34 false false R35.htm 00000035 - Disclosure - Share-based Payments - Summary of Stock Options Activity (Details) Sheet http://akersbio.com/role/Share-basedPayments-SummaryOfStockOptionsActivityDetails Share-based Payments - Summary of Stock Options Activity (Details) Details 35 false false R36.htm 00000036 - Disclosure - Share-based Payments - Summary of Restricted Stock Units Activity (Details) Sheet http://akersbio.com/role/Share-basedPayments-SummaryOfRestrictedStockUnitsActivityDetails Share-based Payments - Summary of Restricted Stock Units Activity (Details) Details 36 false false R37.htm 00000037 - Disclosure - Share-based Payments - Summary of Warrant Activity (Details) Sheet http://akersbio.com/role/Share-basedPayments-SummaryOfWarrantActivityDetails Share-based Payments - Summary of Warrant Activity (Details) Details 37 false false R38.htm 00000038 - Disclosure - Equity (Details Narrative) Sheet http://akersbio.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://akersbio.com/role/Equity 38 false false R39.htm 00000039 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://akersbio.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://akersbio.com/role/CommitmentsAndContingenciesTables 39 false false R40.htm 00000040 - Disclosure - Commitments and Contingencies - Schedule of Lease Commitments (Details) Sheet http://akersbio.com/role/CommitmentsAndContingencies-ScheduleOfLeaseCommitmentsDetails Commitments and Contingencies - Schedule of Lease Commitments (Details) Details 40 false false R41.htm 00000041 - Disclosure - Related Parties (Details Narrative) Sheet http://akersbio.com/role/RelatedPartiesDetailsNarrative Related Parties (Details Narrative) Details http://akersbio.com/role/RelatedParties 41 false false R42.htm 00000042 - Disclosure - Revenue Information (Details Narrative) Sheet http://akersbio.com/role/RevenueInformationDetailsNarrative Revenue Information (Details Narrative) Details http://akersbio.com/role/RevenueInformationTables 42 false false R43.htm 00000043 - Disclosure - Revenue Information - Schedule of Revenue by Product Lines (Details) Sheet http://akersbio.com/role/RevenueInformation-ScheduleOfRevenueByProductLinesDetails Revenue Information - Schedule of Revenue by Product Lines (Details) Details 43 false false R44.htm 00000044 - Disclosure - Revenue Information - Schedule of Revenue by Geographic Area Determined Based On Location of Customers (Details) Sheet http://akersbio.com/role/RevenueInformation-ScheduleOfRevenueByGeographicAreaDeterminedBasedOnLocationOfCustomersDetails Revenue Information - Schedule of Revenue by Geographic Area Determined Based On Location of Customers (Details) Details 44 false false R45.htm 00000045 - Disclosure - Employee Benefit Plan (Details Narrative) Sheet http://akersbio.com/role/EmployeeBenefitPlanDetailsNarrative Employee Benefit Plan (Details Narrative) Details http://akersbio.com/role/EmployeeBenefitPlan 45 false false R46.htm 00000046 - Disclosure - Subsequent Event (Details Narrative) Sheet http://akersbio.com/role/SubsequentEventDetailsNarrative Subsequent Event (Details Narrative) Details http://akersbio.com/role/SubsequentEvent 46 false false All Reports Book All Reports aker-20190630.xml aker-20190630.xsd aker-20190630_cal.xml aker-20190630_def.xml aker-20190630_lab.xml aker-20190630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true ZIP 61 0001493152-19-012548-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-012548-xbrl.zip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end